



Year: 2023

Hot topics in allergen immunotherapy, 2023: Current status and future perspective

Zemelka-Wiacek, Magdalena ; Agache, Ioana ; Akdis, Cezmi A ; Akdis, Mübeccel ; Casale, Thomas B ; Dramburg, Stephanie ; Jahnz-Rózyk, Karina ; Kosowska, Anna ; Matricardi, Paolo M ; Pfaar, Oliver ; Shamji, Mohamed H ; Jutel, Marek

Abstract: The importance of allergen immunotherapy (AIT) is multifaceted, encompassing both clinical and quality-of-life improvements and cost-effectiveness in the long term. Key mechanisms of allergen tolerance induced by AIT include changes in memory type allergen-specific T- and B-cell responses towards a regulatory phenotype with decreased Type 2 responses, suppression of allergen-specific IgE and increased IgG₁ and IgG₄, decreased mast cell and eosinophil numbers in allergic tissues and increased activation thresholds. The potential of novel patient enrolment strategies for AIT is taking into account recent advances in biomarkers discoveries, molecular allergy diagnostics and mobile health applications contributing to a personalized approach enhancement that can increase AIT efficacy and compliance. Artificial intelligence can help manage and interpret complex and heterogeneous data, including big data from omics and non-omics research, potentially predict disease subtypes, identify biomarkers and monitor patient responses to AIT. Novel AIT preparations, such as synthetic compounds, innovative carrier systems and adjuvants, are also of great promise. Advances in clinical trial models, including adaptive, complex and hybrid designs as well as real-world evidence, allow more flexibility and cost reduction. The analyses of AIT cost-effectiveness show a clear long-term advantage compared to pharmacotherapy. Important research questions, such as defining clinical endpoints, biomarkers of patient selection and efficacy, mechanisms and the modulation of the placebo effect and alternatives to conventional field trials, including allergen exposure chamber studies are still to be elucidated. This review demonstrates that AIT is still in its growth phase and shows immense development prospects.

DOI: <https://doi.org/10.1111/all.15945>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-254383>

Journal Article

Published Version



The following work is licensed under a Creative Commons: Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.










Originally published at:

Zemelka-Wiacek, Magdalena; Agache, Ioana; Akdis, Cezmi A; Akdis, Mübeccel; Casale, Thomas B; Dramburg, Stephanie; Jahnz-Rózyk, Karina; Kosowska, Anna; Matricardi, Paolo M; Pfaar, Oliver; Shamji, Mohamed H; Jutel, Marek (2023). Hot topics in allergen immunotherapy, 2023: Current status and future perspective. *Allergy: Epub ahead of print*.

DOI: <https://doi.org/10.1111/all.15945>

REVIEW

Hot topics in allergen immunotherapy, 2023: Current status and future perspective

Magdalena Zemelka-Wiacek¹  | Ioana Agache²  | Cezmi A. Akdis³  |
 Mübeccel Akdis³  | Thomas B. Casale⁴  | Stephanie Dramburg⁵  |
 Karina Jahnz-Różyk⁶  | Anna Kosowska^{1,7}  | Paolo M. Matricardi⁵  |
 Oliver Pfaar⁸  | Mohamed H. Shamji⁹  | Marek Jutel^{1,7} 

¹Department of Clinical Immunology, Wrocław Medical University, Wrocław, Poland

²Faculty of Medicine, Transylvania University, Brasov, Romania

³Swiss Institute of Allergy and Asthma Research (SIAF), University Zurich, Davos, Switzerland

⁴Departments of Medicine and Pediatrics and Division of Allergy and Immunology, Joy McCann Culverhouse Clinical Research Center, University of South Florida, Tampa, Florida, USA

⁵Department of Pediatric Respiratory Care, Immunology and Critical Care Medicine, Charité Universitätsmedizin Berlin, Berlin, Germany

⁶Department of Internal Diseases, Pneumology, Allergology and Clinical Immunology, Military Institute of Medicine-National Research Institute, Warsaw, Poland

⁷ALL-MED Medical Research Institute, Wrocław, Poland

⁸Section of Rhinology and Allergy, Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Marburg, Philipps-Universität Marburg, Marburg, Germany

⁹Allergy and Clinical Immunology, National Heart and Lung Institute, Imperial College London, London, UK

Correspondence

Marek Jutel and Magdalena Zemelka-Wiacek, Department of Clinical Immunology, Wrocław Medical University, Wrocław, Poland.
 Email: marek.jutel@all-med.wroclaw.pl and magdalena.zemelka-wiacek@umw.edu.pl

Funding information

Ministry of Health, Grant/Award Number: SUBZ.A020.22.060

Abstract

The importance of allergen immunotherapy (AIT) is multifaceted, encompassing both clinical and quality-of-life improvements and cost-effectiveness in the long term. Key mechanisms of allergen tolerance induced by AIT include changes in memory type allergen-specific T- and B-cell responses towards a regulatory phenotype with decreased Type 2 responses, suppression of allergen-specific IgE and increased IgG₁ and IgG₄, decreased mast cell and eosinophil numbers in allergic tissues and increased activation thresholds. The potential of novel patient enrolment strategies for AIT is taking into account recent advances in biomarkers discoveries, molecular allergy diagnostics and mobile health applications contributing to a personalized approach enhancement that can increase AIT efficacy and compliance. Artificial intelligence can help manage and interpret complex and heterogeneous data, including big data from omics and non-omics research, potentially predict disease subtypes, identify biomarkers and monitor patient responses to AIT. Novel AIT preparations, such as synthetic compounds, innovative carrier systems and adjuvants, are also of great promise. Advances in clinical trial models, including adaptive, complex and hybrid designs as

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2023 The Authors. *Allergy* published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.

well as real-world evidence, allow more flexibility and cost reduction. The analyses of AIT cost-effectiveness show a clear long-term advantage compared to pharmacotherapy. Important research questions, such as defining clinical endpoints, biomarkers of patient selection and efficacy, mechanisms and the modulation of the placebo effect and alternatives to conventional field trials, including allergen exposure chamber studies are still to be elucidated. This review demonstrates that AIT is still in its growth phase and shows immense development prospects.

KEYWORDS

allergen immunotherapy (AIT), biomarkers, efficacy endpoint, novel vaccines, trial design

1 | INTRODUCTION

Allergen immunotherapy (AIT) was initially reported at the beginning of the 20th century and performed in clinical routine for more than 110 years.¹ A high level of evidence for its efficacy and safety has been elaborated throughout the recent decades for various forms of application, sublingual (SLIT) and subcutaneous (SCIT), as well as oral immunotherapy (OIT), the latter being used in managing food allergies, especially peanut, cow's milk and hen's egg allergy (Table 1).^{2–7} Also, new administration routes, like patches applied on back—epicutaneous immunotherapy (EPIT) or direct injection into lymph nodes (intralymphatic immunotherapy [ILIT])—are clinically effective.^{8–11} The major aim of AIT is achieving immune tolerance to allergens, which can be defined as a long-term clinical tolerance towards natural exposure or in vivo challenges, including allergen exposure chambers (AEC).²

The core strength of AIT lies in its ability to provide sustained relief from symptoms and prevent the progression from allergic rhinitis to asthma—particularly crucial in paediatric populations.^{12,13} This enduring impact can be attributed to AIT's unique ability to trigger a cascade of desensitization mechanisms, which can be achieved by modulating both innate and adaptive immunity.¹⁴ The effectiveness assessment evokes the concept of theratypes, which delineate therapy responders and non-responders based on a comprehensive understanding of pathophysiological mechanisms dictating disease manifestation and response to therapy in various patient groups.¹⁵

AIT is a well-established treatment for specific allergic conditions in Europe. The European Academy of Allergy and Clinical Immunology (EAACI) provided guidelines for AIT with respect to allergic disease and sensitization to specific allergens including insect venom.¹⁶ Also, the peanut OIT has been approved by The European Commission in paediatric patients.¹⁷ There are ongoing trials in food allergy aiming at widening indications for this treatment modality.

This review presents an in-depth insight into the latest developments in AIT while envisioning the key trajectories for its future progress and growth. Along with delving into the novel developments in AIT preparations, we underscore the critical role of clinical and biomarker endpoints' definition and assessment, including the extension to real-world data (RWD) and evidence (RWE), big data management and application of artificial intelligence (AI), the new methodology of clinical trials, disease endotypes and application of biologicals, personalized approaches as well as pharmacoeconomics.

2 | MECHANISMS OF TOLERANCE IN AIT

Allergen-specific immune response studies have demonstrated changes in memory type allergen-specific T- and B-cell responses, regulation of allergen-specific IgE and IgG, as well as mast cell and basophil activation thresholds that do not cause symptoms anymore, and have been demonstrated as putative mechanisms of allergen tolerance (Figure 1A,B).^{18–21} Prevention of new allergen sensitizations and avoidance of progression to more severe diseases, such as the development of asthma after allergic rhinitis,²² is the main clinical implications of immune tolerance.^{23,24} Studies during the last three decades have demonstrated evidence that allergen tolerance utilizes similar mechanisms as shown in other diseases, such as autoimmunity, tumour tolerance and organ transplantation.^{25,26}

2.1 | T_{REG} cells and allergen tolerance

Clinical allergen tolerance linked to immune tolerance was investigated in allergic tissue biopsies and skin late-phase responses. A decrease in allergen-specific cells, in particular, Type 2 T-helper (T_H2) cells and eosinophils during AIT and a parallel increase in T regulatory (T_{REG}) cells and their cytokines in allergic tissues were reported in asthma and allergic rhinitis.²⁷ In murine models, the essential role of T_{REG} cells in inducing and maintaining immune tolerance has been demonstrated, where their adoptive transfer was shown to prevent or cure several T-cell-mediated disease models, including asthmatic lung inflammation, autoimmune diseases and allograft rejection.²⁸ Both subcutaneous and sublingual AIT are shown to induce peripheral T-cell tolerance, characterized by the generation of allergen-specific Treg cells and a decrease in Th2 and Th1 cells.^{29–32} Interleukin (IL)-10, IL-35, tumour necrosis factor-beta (TGF- β), cytotoxic T-cell antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1) with programmed death-ligand 1 (PD-L1)-interactions were proposed as main molecular players.^{33,34} Increased numbers of forkhead box P3 (Foxp3)⁺ cluster of differentiation (CD)3⁺ CD25⁺ cells after AIT of allergic rhinitis, their association with clinical efficacy and suppression of seasonal allergic inflammation strengthen the concept of T_{REG} cell-mediated allergen tolerance in humans.³⁵ In addition, CD4⁺CD25⁺ T_{REG} cells from atopic donors have a reduced capability to suppress the proliferation of CD4⁺CD25⁻ T cells.³⁶ A marked loss of IL-4-producing T cells and

TABLE 1 AIT routes of exposure.

Route of exposure	Description	Duration	Uses	Safety
SCIT	Injecting small and gradually increasing doses of the allergen under the skin, usually in the upper arm	Typically, patients first go through a 'build-up' phase, which may last several months, followed by a 'maintenance' phase where the allergen dose remains consistent	Effective for various allergic conditions, including allergic rhinitis, allergic asthma and stinging insect allergies	Risk of systemic reactions, which can occasionally be severe (anaphylaxis)
SLIT	Placing a tablet or drop containing the allergen under the tongue	Daily administration is common, but the duration can vary based on the specific product	Approved for certain seasonal and perennial allergens (e.g. grass pollen, house dust mites)	Good safety profile with local side effects (e.g. mouth itching or swelling), the risk of severe systemic reactions is lower than with SCIT
OIT	Consuming the allergen in gradually increasing amounts, often mixed with food	The 'build-up phase' usually lasts for several months, and the maintenance dose may last for several years	Aims to increase the threshold of exposure to the allergen required to trigger a reaction	Side effects can range from mild (mouth itching) to severe (anaphylaxis)
EPIT	Delivers allergen through the skin using a patch	Clinical trials for 12 months, then up to 60 months of open-label treatment	Mainly being investigated for food allergies (not approved)	Most reactions are skin-related (e.g. local redness or itching)
ILIT	Injecting allergen directly into lymph nodes	Typically, three injections over several months	Initial studies have targeted allergic rhinitis and pollen allergies	Side effects can range from mild (lymph node enlargement) to severe (anaphylaxis)

Abbreviations: AIT, allergen immunotherapy; EPIT, epicutaneous AIT; ILIT, intralymphatic AIT; OIT, oral AIT; SCIT, subcutaneous AIT; SLIT, sublingual AIT.

the acquisition of IL-10-producing and FoxP3⁺ antigen-specific CD4⁺ T-cells.^{37,38} The role of T_{REG} cells in allergen tolerance has also been shown in T-cell epitope peptide AIT.³²

2.2 | B_{REG} cells and allergen tolerance

IL-10-producing regulatory B (B_{REG}) cells suppress immune responses, and the lack of these cells exacerbates symptoms in mouse models of chronic inflammation, transplantation and chronic infection.³⁹ Inducible IL-10-secreting B regulatory 1 (B_{REG}1) cells express high surface CD25 and CD71 and low CD73 levels, produce high levels of IL-10 and potently suppress antigen-specific CD4⁺ T-cell proliferation. Furthermore, the frequency of IL-10⁺ phospholipid antigen-specific (PLA)-B cells increased in allergic patients receiving AIT. The suppressive B cells and immunoglobulin class G (IgG)4-expressing B cells are both confined to IL-10⁺ BR1 cells in human subjects.³⁹ IL-10-overexpressing B cells demonstrate a prominent immunoregulatory profile comprising upregulation of suppressor of cytokine signalling 3 (SOCS3), glycoprotein A repetitions predominant (GARP), the IL-2 receptor alpha chain (CD25) and PD-L1. Furthermore, IL-10-overexpressing B cells secrete less IgE and potently suppress proinflammatory cytokines in peripheral blood mononuclear cells (PBMC), maturation of monocyte-derived dendritic cells (rendering their profile to regulatory phenotype) and antigen-specific proliferation.⁴⁰

2.3 | Regulation of mast cells, basophils and eosinophils by AIT

Although there are individual differences and risks for developing systemic anaphylaxis during the course of AIT, the suppression of mast cells and basophils continues to be affected by changes in other immune parameters, such as the generation of allergen-specific T_{REG} cells and decreased specific IgE. Significantly enhanced tryptophan degradation and elevated human Ig receptors inhibitory transcript (ILT4) expression in monocytes were found within a few hours after the first injection on Day 1, representing markers of very early changes.⁴¹ In addition, early reduction in basophil sensitivity predicts symptom relief with grass pollen AIT.⁴² Furthermore, the basophil expression of diamine oxidase significantly increases after AIT and is suggested as a novel biomarker.⁴³

2.4 | Innate lymphoid cells and AIT

Type 2 innate lymphoid cells (ILC2) play a key role in asthma and upper respiratory inflammation.⁴⁴ Type 2 immunity (T2) consists of GATA-3⁺ ILC2s, Type 2 T cytotoxic (T_C2) cells and T_H2 cells producing IL-4, IL-5 and IL-13, which induce mast cell, basophil and eosinophil activation, as well as IgE antibody production, thus protecting against helminths and venoms.⁴⁵ Seasonal increases in peripheral ILC2s are inhibited by grass pollen SCIT.⁴⁶ Recently discovered IL-10





FIGURE 1 (A) Immunologic changes during the course of AIT. Starting with the first injection/tablet, decreases in mast cell and basophil activity, degranulation and tendency for systemic anaphylaxis degranulation occur within the first hours. This is followed by the generation of allergen-specific T_{REG} , B_{REG} and ILC_{REG} cells and the suppression of allergen-specific T_{H1} and T_{H2} cells and innate ILC2. Specific IgE shows an early increase and decreases relatively late. These events are in parallel to increases in IgG_4 that continuously increase as long as the treatment continues. Also, an increase in local and systemic $IgA_{1/2}$ is noticed. After several months, the allergen-specific IgE/IgG_4 ratio decreases. T_{FR} cells restrict T_{FH} cell-mediate IgE antibody production. After a few months, decreases in tissue mast cells and eosinophils lead to reductions in released mediators and skin late-phase response occurs. DC_{REG} cells can help differentiate naive T cells into T_{REG} cells and shift T_{H2} to T_{H1} responses. A significant decrease in Type I skin test reactivity is also observed relatively late in the course. It has to be noted that there is significant variation between donors and protocols sometimes leading to variability in results. (B) Role of regulatory cells in the suppression of allergic inflammation. The balance between T2 cells and regulatory cells is critical for the development or suppression of allergic inflammation. Regulatory cells and their cytokines suppress T2 immune responses and contribute to controlling allergic diseases in several major ways. Red arrows indicate the regulatory and suppressive effects of T_{REG} , B_{REG} , DC_{REG} , ILC_{REG} and T_{FR} cells, which exert their regulatory functions directly or indirectly on B cells by inducing IgG_4 and IgA and suppressing IgE; on vascular endothelium by suppressing T_{H2} cell homing to tissues; on mast cells, basophils and eosinophils via direct and indirect suppressive effects; and on, direct and indirect, suppression of epithelial cell activation and proinflammatory properties. In addition, B_{REG} cells also suppress effector T cells and contribute to IgG_4 synthesis. AIT, allergen immunotherapy; B, lymphocytes B cell; Bas, basophil; B_{REG} , B regulatory cells; DC_{REG} , tolerogenic Dendritic cells; Eos, eosinophil; IL, interleukin; ILC, innate lymphoid cells; ILC_{REG} , regulatory innate lymphoid cells; MC, mast cell; pDC, plasmacytoid dendritic cells; SCIT, subcutaneous AIT, (s)IgE/ $A_{1/2}/G_4$, (specific) immunoglobulin class E/ $A_{1/2}/G_4$; SLIT, sublingual; T_{FH} , follicular T helper cells; T_{FR} , T follicular regulatory cell; $T_{H1/2}$, T lymphocyte type 1/2; T, lymphocytes T; T_{REG} , T regulatory cells.

expression suppressive ILCs,⁴⁷ namely the regulatory ILCs (ILC_{TEG}) increase during AIT.⁴⁵

2.5 | Modulation of allergen-specific IgE and IgG responses during AIT

Early increase in specific IgG Abs, particularly IgG_4 and late decrease in specific IgE are classically observed in AITs.^{48,49} It is highly possible that the decrease in IgE/IgG_4 ratio during AIT is a feature of skew from allergen-specific T_{H2} to T_{REG} cell predominance. IL-10 is a potent suppressor of both total and allergen-specific IgE, while it simultaneously increases IgG_4 production.^{29,50} In house dust mite (HDM)-AIT, IgG_2 induction and correlation with IgG_4 and IgE have been proposed to indicate high therapy response.⁵¹ There are several features of IgG_4 , which may play a role in its non-inflammatory role. The two arms of IgG_4 have the ability to separate and repair by antigen-binding fragment (Fab) arm exchange that leads to bi-specific antibodies that are functionally monomeric.^{52,53} Furthermore, IgG_4 does not fix complement and can inhibit immune-complex formation by other isotypes, giving this isotype anti-inflammatory characteristics. The nasal and systemic $IgA_{1/2}$ antibody levels during SLIT are increased.⁵⁴

In addition to T_{H2} cells, follicular helper T (T_{FH}) cells are crucial in controlling IgE production. In contrast, follicular regulatory T (T_{FR}) cells, a specialized subset of T_{REG} cells resident in B-cell follicles, restrict T_{FH} cell-mediated help in extrafollicular antibody production, germinal centre formation, immunoglobulin affinity maturation and long-lived, high-affinity plasma and memory B-cell differentiation.³⁸ Upregulation of T_{FH} cell activities, including a skewing toward Type 2 T_{FH} (T_{FH2}) and IL-13 producing T_{FH} (T_{FH13}) phenotypes, and defects in T_{FR} cells have been identified in patients with allergic diseases. AIT reinstates the balance between T_{FH} and T_{FR} cells in patients with allergic diseases, resulting in clinical benefits.⁵⁵

3 | NOVEL PATIENT ENROLMENT STRATEGIES

The precision medicine approach is essential to successful AIT. The key elements include precise definitions of disease phenotype and endotype.⁵⁶ It is essential to discern who is most likely to benefit from AIT. Novel diagnostic tools and biomarker validation enable the better selection of patients for treatment in this respect distinguishing between responder and non-responder patients. In a larger sense, the tailored approach should incorporate adjustments to each patient's personal and human (personomics, humanomics) background. This ensures optimal treatment efficacy (Figure 2).

3.1 | Novel biomarkers and clustering

Biomarkers, whether determined in vivo or in vitro, have emerged as a critical tool in the field of precision medicine for predicting clinical outcomes. The ideal biomarker samples should be collected at the point of care using quick and noninvasive methods, and the assessment should be cost-efficient.⁵⁶ Data from one disease can be meta-analyzed across diseases using breakthrough AI algorithms, expediting the development of new biomarkers for responsiveness or non-responsiveness to medication or novel targets for therapeutic intervention based on molecular pathway similarity.⁵⁷ Although there are currently no validated biomarkers to indicate a good response to AIT, research has revealed distinctions between responder and non-responder patients.²⁶ Potential AIT biomarkers are shown in Table 2.

Cluster analysis, a part of unsupervised learning, can uncover hidden patterns in complex data sets and provide novel insights into allergy and asthma sub-phenotypes and the underlying mechanisms of these conditions.⁵⁸ It allows us to find natural groupings




FIGURE 2 Novel approaches for successful AIT. Personalized medicine allows the selection of treatment that is most likely to benefit patients based on understanding their disease phenotype and endotype. Current AIT approaches aim to identify specific biomarkers, including patient sensitization at the molecular level aiming at cluster analysis. Cluster analysis is a statistical tool that groups patients into clusters based on their similarities. In the context of allergies, patients might be grouped based on shared symptoms, biomarkers or responses to different treatments. AIT, allergen immunotherapy.

that are difficult to identify manually, especially in high-dimensional data. The strength of these findings lies in their potential to enable personalized diagnosis, treatment and prevention strategies.

Clustering algorithms can effectively identify *ex vivo* predictive biomarkers in peanut allergy. A high-resolution view of immune cell populations and their changes during diagnostic oral food challenges reflects the dynamic of inflammation processes. It potentially provides a safer, more efficient method for monitoring therapeutic interventions like OIT.⁵⁹

3.2 | Applications of mobile Health (mHealth)

Digital Health will greatly impact different aspects of AIT,⁷² including a better selection of patients to be treated, a more precise selection of allergens and improved monitoring of adherence to

treatment, side effects and clinical efficacy. Baseline monitoring of pollen exposure and disease severity is facilitated by dedicated electronic (e)Diaries, such as MASK-Air,⁷³ AllergyMonitor,⁷⁴ Hustenblume⁷⁵ and others. They allow patients to daily record their symptoms, quality of life, and drug intake so that trajectories of internationally validated severity scores, such as daily symptom score (dSS), combined symptom medication score (CSMS), visual analogue scale (VAS), are made available to the doctor through comprehensive reports.^{76,74} Through this, doctors can get prospective information on disease severity and symptom control achieved via preventive measures and therapeutic intervention.^{77,78} On the other hand, by matching trajectories of disease severity against those of pollen counts, doctors get more precise insights into a potential causal-effect relationship between one specific pollen and the patient's symptoms.⁷⁹ Some eDiaries also allow daily registration of AIT side effects, which can be particularly useful for prompt clinical evaluation and, if necessary,

TABLE 2 Potential biomarkers for the AIT efficacy, stratification and efficacy prediction.

Biomarker	AIT efficacy	Ref.
Basophil response to allergens	A valuable tool for monitoring the effects of AIT. A decrease in basophil sensitivity after 3 weeks of SCIT predicted long-term improvement in seasonal SMS	60
IL-10 ⁺ CTLA-4 ⁺ ILCs	This subset of ILCs showed an increase after 24 months of AIT in patients with AR triggered by HDM. The increase is correlated with the SMS	61,62
CD29 ⁺ (beta 1 integrin ITGB1) B memory cells	CD29 is upregulated on two unique subsets of allergen-specific B memory cells after 4 months of SLIT for grass pollen allergy. It can be used as an early biomarker for treatment effects	63
Surface IgG ₄ and CD23 ⁺ (FCER2) B memory cells	An increase in the proportion of allergen-specific B memory cells expressing surface IgG ₄ and CD23 was seen after SLIT. It is indicative of changes due to the treatment	
CD38 ⁺ B cells	Their presence is associated with poor therapeutic effects of AIT in AR patients. CD38 ⁺ B cells convert T _{REG} cells into T _H 17 cells. CD38 ⁺ B-cell frequency was negatively correlated with T _{REG} and T _{FR} cells frequencies	64
IgA ₁ in nasal fluid	This correlates with the suppression of nasal symptoms during SLIT	65
Serum IgA, IgE, IgG ₄	These, added to other parameters, enhance the ability to identify non-responsive patients in the second year of AIT	
Mast cell functional assay	A new method using passive sensitization of transgenic mast cells with patient serum. This might assess AIT treatment effectiveness and longevity of response	66
Metabolic biomarkers (eicosanoids, 12(S)-HETE, 15(S)-HETE)	Monitors AIT response in allergic asthma or AR. Their levels increased in the first year of SCIT treatment and then decreased from Years 1 to 3	67,68
Biomarker	AIT stratification/efficacy prediction	Ref.
CD4 ⁺ CD25 ⁺ FoxP3 ⁺ CD127 ⁻ cells	The increase in the frequency of CD4 ⁺ CD25 ⁺ FoxP3 ⁺ CD127 ⁻ cells after the AIT, and the low level of cells at the onset of AIT correlate with better treatment efficacy	69
T2 cells (IL-4 ⁺ -IL-13 ⁺ -CD4 ⁺ cells)	Predictive of peanut and baked egg tolerance before AIT. High egg-specific T2 cells frequency is most predictive of oral AIT failure	70
Chemokine receptor protein 6 (CCR6 ⁺) cells	These were not predictive of peanut and baked egg tolerance at baseline	
Bronchial allergen challenge	Biomarker for AIT in asthma, specifically the response to the early (EAR) and late asthmatic reaction (LAR). Reduction in response was reported, and those who develop a dual response (EAR and LAR) with high eosinophilic inflammation are more likely to respond to AIT	13
Serum periostin levels	High levels are associated with an effective response to SLIT. The improvement of the rhinoconjunctivitis quality of life questionnaire (RQLQ) directly correlated with the serum periostin level	71

Abbreviations: +, presence; -, absence; AIT, allergen immunotherapy; AR, allergic rhinitis; B, B lymphocyte cell; CD, cluster of differentiation; HDM, house dust mite; HETE, hydroxyeicosatetraenoic acid; IgA/E/G, immunoglobulin class A/E/G; IL-10, interleukin 10; ILC, innate lymphoid cell; SCIT, subcutaneous AIT; SLIT, sublingual AIT; SMS, symptom-medication score; T2, Type 2 immune response; T_{FR}, T follicular regulatory cell; T_{REG}, T lymphocyte regulatory cells.

intervention or AIT dosage modulation. Moreover, the possibility to record daily medication intake provides real-time information on adherence, for example, to SLIT.^{80,81} This gives the allergist a chance to support a reluctant patient by him/her with convincing information on the importance of adherence to AIT. Last but not least, disease severity trajectories during the baseline pollen season compared to those of seasons during or following AIT treatment, may give information on the level of treatment efficacy.

3.3 | Molecular allergy diagnostics

The most known benefit of the molecular allergy IgE tests (also designated 'component resolved diagnostics'—CRD) in the diagnostic work-up of allergic patients is their potential to differentiate genuine primary sensitizations from cross-reactivity due to

the presence of IgE towards panallergens.⁸² This is primarily useful for patients with many positive extract-based test results or those with an inconclusive clinical history. As a targeted prescription of AIT is often difficult, if not impossible, for those patients, additional information on the molecular IgE profile can reduce the number of primary elicitors and facilitate the choice of suitable therapeutic preparations.^{83,84} Further, allergens of low abundance in the source material may be underrepresented or even missing in extract-based test solutions (Figure 3). As this may also be the case for batches of therapeutic preparations, knowledge of the width of a patient's molecular IgE profile may provide valuable information to estimate the chances of treatment success.^{85,86} In addition, the presence of IgE to certain molecules may serve as a clinical risk marker (e.g. sIgE to Der p 23—house dust mite (HDM)⁸⁷ or Phl p 7—timothy grass⁸⁸ as risk markers for asthma), facilitating the decision on AIT prescription, also in a potential setting of




FIGURE 3 Utility of allergen extracts and allergenic molecules for the diagnostic work-up. Extract-based diagnostics are more suitable for: (A) mono/limited oligo sensitizations (B) and/or minor clinical risks (C) as well as a high abundance of molecules in the suspected allergen source (D) and/or allergens of high stability. The use of allergenic molecules should be considered in cases of polysensitizations and/or allergen triggers associated with high clinical risks and low abundant and/or labile allergenic molecules in the extract. Reprinted with permission.⁹⁰ IgE, immunoglobulin E.

tertiary prevention.⁸⁹ While our knowledge of new (pan)allergens and their clinical relevance is constantly growing, structured information is important for clinicians and researchers alike. For example, an updated summary of allergen molecules and their use in allergy diagnosis and AIT prescription is now available in the 2nd edition of the EAACI Molecular Allergy User's Guide.⁹⁰

4 | NEW METHODOLOGY FOR CLINICAL RESEARCH

The classical type of experimental design is randomized controlled trials (RCTs), where participants are randomly assigned to one of two or more groups: (1) an experimental group, which receives the intervention or treatment under investigation; or (2) a control group, which receives a placebo treatment (participants are blinded to their allocations), in addition to standard care or no intervention. The random assignment helps to ensure that any differences between groups are due to the intervention itself and no other variables, thus reducing potential bias and confounding factors. However, enrolled participants differ from one another in known and unknown ways that can influence study outcomes, and cannot be directly controlled.⁹¹

Lately, there has been interest in novel trial designs, for more flexibility, efficiency, and cost-effectiveness. One of them is adaptive trial design, a type of clinical trial that allows for prospectively planned modifications to one or more aspects of the design based on accumulating data from subjects in the trial. These changes can be made based on observations from the data collected during the trial.⁹² Adaptations can involve one or more aspects of the trial, such

as sample size re-estimation, number of treatment arms (adding or stopping early), randomization ratio, modification in inclusion/exclusion criteria or modification in statistical hypothesis.⁹³ Another group of trials are complex clinical trials, which allow the evaluation of more than one or two therapies in more than one patient type or disease within the same overall trial structure. This design includes multiple targeted therapies in the context of a single disease (umbrella study), single targeted therapies in the context of multiple diseases (basket study), or multiple targeted therapies in the context of a single disease that allows different therapies to enter or leave the platform (platform studies); all based on the master protocol overreaching to answer multiple study questions.⁹⁴ However, these designs may be a source of bias, that can influence participants as well as investigator behaviour, and statistical estimates, also the study integrity may be damaged.⁹⁵

There are also hybrid approaches that incorporate elements from multiple types of trial designs. It could involve a study design that has elements from both RCTs and adaptive trials.

There are not a lot of adaptive or complex studies in AIT. A three-stage design for AIT trials was developed to avoid maintaining the control arm on placebo for the course of the study, which can result in numerous dropouts, while still allowing for a stage-wise statistical evaluation to test for benefit at the end of each stage. The placebo group in Stage 1 becomes the active treatment group in Stage 2. In Stage 3, AIT is stopped to see if benefits are maintained after therapy.⁹⁶

Another type of clinical data is real-world data (RWD) which refers to information that is collected outside the confines of RCTs.⁹⁷ RWD can come from various sources, such as electronic health records, insurance claim databases, patient registries, health surveys,

wearable devices and even social media posts.⁹⁸ When RWD is systematically analyzed, it generates real-world evidence (RWE), which can provide insights into a treatment's effectiveness, safety and cost-effectiveness in everyday clinical practice.⁹⁹

RCTs and RWE complement each other in several ways. RCTs are considered the gold standard for determining a treatment's efficacy because they control for confounding variables through randomization and maintain strict protocols for treatment administration.^{97,100} However, the patient populations in RCTs are often carefully selected and may not fully represent the diversity of patients seen in real-world clinical practice. RWE studies provide evidence from larger, more diverse and unselected patient populations, and the treatment is given under routine clinical conditions. This means RWE can capture a broader range of patient experiences, from different demographics to those with comorbidities, thus providing insights into how a treatment performs in 'real-life' conditions.

The application of RWE shows some limitations. The quality and completeness of RWD can vary greatly, depending on the data source and collection methods. There might be errors or gaps in data, and missing data can introduce bias. Because RWD is observational, it may not be possible to establish a clear cause-effect relationship as in RCTs. Variability in clinical practice can introduce confounding factors that are hard to control for in the analysis.¹⁰¹

Several AIT registries have been developed to provide consistent, high-quality RWD, such as the British Society for Allergy and Clinical Immunology—BSACI Registry for ImmunoTherapy (BRIT)¹⁰² and the OmaBASE registry,¹⁰³ or Danish National Health Service Prescription Database and Statistics Denmark Database.¹⁰⁴ These registries are helping to further our understanding of the safety and efficacy of AIT and biologicals for allergies and urticaria in real-world settings.

RCTs have shown that AIT is effective in reducing allergy symptoms, and RWD-based studies have provided evidence that these benefits can extend to the long term and in diverse patient groups.¹⁰⁵⁻¹⁰⁸ Additionally, in patients with concurrent asthma, AIT was associated with a reduced likelihood of asthma exacerbations and pneumonia.¹⁰⁹ RWD of persistence and adherence rates showed for SCIT and SLIT significant variability depending on the study methodology and duration of follow-up.^{110,111} Furthermore, RWD can capture the effectiveness of AIT in reducing healthcare costs and the rates of adherence to therapy, areas often not covered in RCTs.¹¹²⁻¹¹⁴

5 | METHODS IN AIT DEVELOPMENT PROGRAMS: CURRENT STANDARDS AND FUTURE NEEDS

In Europe, the regulatory background for the clinical development programs in AIT refer to methodological guidelines by the European Medicines Agency (EMA).^{115,116} These guidelines emphasize a scientific need for further investigations on 'ideal' clinical endpoints (by, e.g. reflecting the clinical relevance of treatment effect sizes

reported), placebo effects and alternatives to conventional field trials.¹¹⁷⁻¹¹⁹

The EAACI has published a consented position paper on 'standardisation of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis' aimed to extract characteristics of different endpoints broadly used in AIT development programs.¹²⁰ The EAACI-Task Force has elaborated a standard definition for a homogeneous CSMS for the primary endpoint in future trials to harmonize this important parameter for the clinical readout of trials.¹²¹ Although frequently used in recent pivotal trials, a formal (clinical) validation of this definition is still needed. Recently published first analyses have used RWD from apps to generate and validate several CSMS definitions. Based on this data, mobile health tools can play an important role in future stratification and follow-up of patients in controlled trials and RWE.¹²² Another study has correlated several patient-reported outcome measures (PROMs) with a validated questionnaire-based tool on data from a pivotal randomized, placebo-controlled trial on SLIT in birch pollen allergic patients.¹²³

The methodological problem in AIT clinical trial programs is a huge placebo effect demonstrated for both SCIT and SLIT application routes in many studies.^{124,125} High response in the placebo arm within controlled trials minimizes the treatment effect size for the investigated AIT product, found in several trials on promising candidates in AIT development.¹²⁶ However, methodological recommendations from learned societies such as the EAACI provide solutions in conducting clinical trials in AIT aimed to minimize the treatment effect of inactive comparators revealing the real potential of future candidates in AIT.¹²⁵

Several confounders impact clinical trials in AIT development programs, such as false reporting of PROMs, imputation of missing data or the role of natural (non-standardized) allergen exposure impacting the outcome of a (field-) trial.¹¹⁶ Allergen provocation under standardized conditions in so-called allergen exposure chambers (AECs) may overcome methodological flaws.¹²⁷ Still, to date, this technology is not clinically validated to replace 'classical' field trials under natural exposure, as emphasized by EMA in the aforementioned guideline.¹²⁸ However, an EAACI task force comprising worldwide clinicians, AEC providers and delegates from regulatory authorities has provided overviews of the similarities and differences of current AEC facilities with the aim of further harmonization.¹²⁹ An important step in this direction has been the compilation of technical validation data reported by international AEC providers, opening the path for the next step of AEC development, the clinical validation, for example, through a hybrid approach.^{130,131}

6 | ADVANCED DATA MANAGEMENT: BIG DATA AND ARTIFICIAL INTELLIGENCE (AI)

Biomedical big data can be broadly classified into two categories: omics and non-omics data. Non-omics data are highly variable and includes epidemiological information, clinical data, lab tests, imaging parameters, environmental monitoring and electronic health records

registered by healthcare professionals.¹³² Collecting data might face difficulties due to data protection regulations. Omics data (such as genomics, epigenomics, transcriptomics, proteomics and metabolomics), generated using high-throughput biological platforms, offers many features at different biological levels, such as DNA, RNA, proteins and metabolites.^{133,134} Challenges arise from the inherent heterogeneity of non-omics data and its subjective nature, which can lead to dataset biases.¹³⁵ While omics data are generally bias-free, its complexity, heterogeneity, dynamics, uncertainty and high dimensionality can pose difficulties in data integration.^{134,136}

The analysis of big data using AI encompasses a variety of processes and techniques, including the investigation of patient data, genetic information, environmental factors and medical records, to uncover potential triggers and risk factors.¹³⁷ This can facilitate early interventions and prevention strategies, improving patient outcomes.¹³⁸ For example, AI can mine clinical trial data, and patient records, published literature, identifying new insights into the mechanisms of allergic reactions and potential therapeutic targets, or can be leveraged for disease subtyping, deriving mechanistic insights or biomarker prediction.¹³⁹ A subset of AI, machine learning (ML), is particularly adept at processing large volumes of intricate data, making unbiased meaning and insights extraction possible.¹⁴⁰ However, building causal genotype–phenotype associations and understanding environmental impact remain computationally challenging.¹⁴¹

AI and ML are currently employed in allergy for various tasks such as monitoring airborne pollen counts and predicting the risks associated with air pollution,¹⁴² a significant contributor to the exacerbation of respiratory diseases.¹⁴³ Also supporting the diagnosis of adverse reactions to drugs or vaccines, improving patient engagement, diagnostic accuracy and personalized treatment plans.^{144,145} AI's capabilities also extend to predicting disease sub-phenotypes in food-allergic patients, aiding in patient stratification into distinct disease or exposure subgroups, risk stratification, cluster analysis and biomarker identification.^{146–148}

A limited number of studies have investigated AIT outcomes. ML-assisted fourier-transform infrared (FTIR) spectroscopy allowed for the discrimination of sera obtained from healthy, allergic and AIT-treated humans, thereby demonstrating its potential for rapid diagnosis of allergy and monitoring of patients. AI can predict the probability of sustained unresponsiveness after milk oral AIT.¹⁴⁹ ML also can enable unbiased phenotyping and identification of cell subsets that are involved in AIT treatment.¹⁵⁰

Despite the immense potential, RWE, passively collected through hospital systems or public health data-capturing procedures, often presents challenges. The issues of data structuring, quality and missing fields can obstruct traditional analysis. However, AI is demonstrating its value by addressing these problems and unlocking the potential within these large and less structured datasets. In the context of allergy and allergen immunotherapy, the use of AI in managing and interpreting such RWD can lead to the development of more personalized and effective therapeutic strategies, paving the way for the next generation of allergy care.^{140,151}

7 | PHARMACO-ECONOMY OF AIT/ COST-EFFECTIVENESS

According to Directive 2001/83/EC, test and therapy allergens are medicinal products in all European Union (EU) member states and are subject to marketing authorizations.^{152,153} Allergic diseases, including allergic rhinoconjunctivitis, asthma and atopic dermatitis, have a significant impact on the health of the individual patient, but also on healthcare costs (direct, indirect and intangible) and the economy as a whole.^{154–160} The role of AIT in the treatment of allergic diseases has been proven on the basis of clinical trials and long-term observations in real practice (RWE), but according to the EMA guidelines, the assessment of the AIT effects should take into account product-by-product treatment of allergy maintenance of efficacy during 2–3 treatment years, long-term efficacy and disease-modifying effect in post-treatment years.^{161,162} Health technology assessment is based on the evaluation of incremental benefits (in terms of clinical efficacy and safety) related to the introduction of technology to clinical practice (comparative effectiveness assessment clinical, relative effectiveness assessment, in relation to the related incremental costs).^{163–166} These analyses allow for the comparison of different therapy methods and single products, facilitate the evaluation of the advantages and disadvantages from an economic point of view, as well as play an important role in decision-making, for example, to support reimbursement decisions.

All forms of pharmacoeconomic studies are available in the current international literature on AIT. Unfortunately, factors such as differences in the methodology, differences in quality of health economic models, lack of studies on various allergens and guidelines of the four-stage approach to assessing the effectiveness of AIT required by EMA make economic assessments incomparable. In addition, AIT effectiveness is strongly dependent on treatment compliance.^{112,167–174}

In Portugal, the cost-effectiveness of SCIT and SLIT in paediatric patients with HDM-triggered allergic asthma was investigated. Both therapies were cost-effective, particularly SCIT, which reduced drug use and exacerbations that required emergency room visits. SLIT had a bigger overall influence on the quality of life.¹⁷⁵ Another study found that SCIT, in combination with inhaled corticosteroids (ICS) was more cost-effective than ICS alone in HDM-induced asthma.¹⁷⁶ Interestingly, switching from SCIT to ILIT for bee venom allergy can result in significant cost savings, potentially halving the treatment costs over 5 years.¹⁷⁷

In 2021, it was suggested that AIT may be cost-effective for people with allergic rhinitis with or without asthma and in high-risk subgroups for venom allergy. No conclusions on the cost-effectiveness of AIT for food allergy were shown in this study.¹⁶⁴ Moreover, in some publications, it is indicated that parameters such as quality-adjusted life year (QALY) and incremental cost-effectiveness ratio (ICER) may not be suitable for the economic assessment of chronic diseases.^{112,166}

These complicated issues could be a challenge both for physicians prescribing allergens and for the payer/regulator in each

country. The Professional Society for health economics and outcomes research (ISPOR) guidelines indicate that cost-effectiveness analysis provides a standardized approach to value assessment. Still, this definition is interpreted differently by each stakeholder—patients, payers, providers or society at large.¹⁷⁸

8 | ADVANCES IN AIT COMPOUND TECHNOLOGY

8.1 | Novel preparations

The extensive research concerning novel preparations in AIT, like recombinant allergens, synthetic peptides (T- and B-cell epitopes), IgG antibodies against allergens, carrier systems or adjuvants, are crucial to improve treatment efficacy, safety and patient compliance.

There are a few types of allergen derivatives that can reduce allergens' allergenicity while retaining their immunogenicity, unlike extracts that are obtained from natural sources that may contain a mix of allergenic and non-allergenic substances.¹⁷⁹ Wild-type recombinant allergens resemble all of the properties of adequate natural allergens, especially IgE-binding. Synthetic and recombinant hypoallergens can exhibit strongly reduced IgE-binding capacity and allergenic activity but contain allergen-specific T-cell epitopes (long synthetic peptides, recombinant hypoallergenic allergen derivatives) or carrier compounds providing T-cell help (peptide carrier-based B-cell epitopes).¹⁸⁰ Allergoids are chemically modified natural allergens, usually by polymerization or treatment with formaldehyde or glutaraldehyde, which show strongly reduced IgE-binding capacity.^{181,182}

Recombinant birch (Bet v 1) allergens have been tested in clinical trials, showing an improvement in clinical symptoms.^{183,184} Hypoallergenic B-cell epitopes based on grass pollen (Phl p 1)

are safe and effective in AIT.^{185–187} Also synthetic T-cell epitope peptides from the major cat allergen Fel d 1,¹⁸⁸ and birch, Bet v 1, can induce symptom reduction.¹⁸⁹ Monoclonal IgG antibodies against the dominant cat allergen Fel d 1 can prevent IgE binding and simultaneously prevent clinical symptoms,¹⁹⁰ and cocktail of antibodies against Bet v 1 can reduce symptoms after nasal challenge.¹⁹¹

Allergoid-mannan conjugates can interact with monocyte differentiation and reprogram them into stable tolerogenic dendritic cells (DC), which in turn could reduce allergic responses. This process involves metabolic and epigenetic changes and promoting T_{REG} cell production.¹⁹²

A very promising approach is provided by modern adjuvant approaches. Adjuvant is a substance or compound that is co-administered with the allergen extract and has the ability to increase allergen immunogenicity and/or modulate the immune response. Adjuvants can be used to reduce the unwanted side effects associated with AIT by slowing allergen diffusion, lowering the risk of anaphylaxis and reducing allergen doses, which decreases the number of required injections, hence enhancing the safety profile. However, adjuvants can cause inflammation at the administration site.¹⁹³ Innovative adjuvants include microbial products such as TLR4-ligand monophosphoryl lipid A (MPLA) that is safe and effective in treating asthma in patients sensitized to olive pollen,¹⁹⁴ flagellin, that enhances immunogenicity and reduces allergenicity for birch AIT,¹⁹⁵ or CpG which has in some studies been shown to be effective in the treatment of allergic rhinitis.¹⁹⁶ Other potential candidates include virus-like particles (VLPs), enhancing immunomodulation during AIT.¹⁹⁷ Notably, HDM-SCIT packaged into VLP with CpG was deemed safe.¹⁹⁸ Nanoparticles, both biocompatible and biodegradable, can act as adjuvants and might carry allergens in their complexes, and shield allergens from enzymatic digestion.^{199,200}

TABLE 3 Biologicals used to support AIT.

Biological	AIT type	Outcomes	Ref.
Dupilumab (anti-IL-4 and IL-13 signalling)	SCIT in AR triggered by grass pollen	Improve SCIT tolerability but did not reduce post-allergen challenge nasal symptoms	202
	HDM-SLIT in asthmatic patients with AR	Benefits in controlling asthma	203
Omalizumab (anti-IgE)	Multifood OIT	Help patients consume multiple foods and allow for dose escalation, decreasing the time required to reach maintenance dosing and adverse effects	204–206
	Aeroallergens AIT in asthmatic patients	Fewer systemic allergic reactions to AIT enabled to achievement the target maintenance dose	207,208
	VIT	Overcoming severe adverse reactions to VIT	209
	Peanut OIT	Adjunctive omalizumab facilitated quicker peanut desensitization, but nearly 50% of patients stopped OIT within 72 months due to adverse reactions	210
Tezepelumab (anti-TSLP)	SCIT in AR triggered by cat allergy	Enhance the efficacy of SCIT and promote tolerance after a 1-year course of treatment	211

Abbreviations: AIT, allergen immunotherapy; AR, allergic rhinitis; HDM, house dust mite; IgE, immunoglobulin E; IL-4R α , interleukin-4 receptor alpha subunit; OIT, oral immunotherapy; SCIT, subcutaneous AIT; SLIT, sublingual AIT; TSLP, thymic stromal lymphopoietin; VIT, venom immunotherapy.

8.2 | Combination of AIT and biologicals

The combination of AIT with biologicals increases the efficacy and safety of the treatment (Table 3). The synergistic influence of AIT and (T2 directed) biologicals shifts the balance toward type 1 immune response (T1). In addition, AIT induces the regulatory mechanisms (regulatory cells), while biologicals influence the effector compartment of T2 inflammation (desensitization of effector cells), so combining both can show an additive effect.²⁰¹

9 | AIT FOR ALLERGIC ASTHMA

The precise pathways supporting the beneficial AIT effects for allergic asthma still remain unclear.^{160,212–214} Thus, it exerts an overall anti-inflammatory effect reflected in the reduction of exacerbations and the dose of inhaled glucocorticosteroids (ICS) needed to control symptoms. There is also a small reduction in non-specific airway hyperresponsiveness (AHR) and a more significant impact on allergen-specific AHR.^{215,216} AIT impacts both the late-phase response, involving the recruitment, activation and persistence of eosinophils and T cells at sites of allergen exposure and the immediate response to allergen provocation which is mast cell mediated.²¹⁷ The impact on lung function is less clear, probably because the small airways compartment was not properly evaluated in clinical trials, which mainly focused on large airways via measurement of forced expiratory volume in the first second (FEV₁) and peak expiratory flow (PEF).²¹⁸ Allergic inflammation can impair interferon (IFN) production via alarmins such as IL-33, T2 cytokines such as IL-4 and IL-13 and allergen/IgE interactions. It is interesting if inhibition of allergic pathways via AIT in allergic asthma can boost the anti-viral IFN production and protect against viral infections.^{219,220}

The results of the RCTs show asthma symptom control, decrease in exacerbations and medication use are currently confirmed by RWEs.^{105,221–223} It has been shown, that HDM-SLIT enhances bronchial epithelial antiviral tolerance against viral infection. These findings could explain why HDM-SLIT is effective at reducing allergic asthma exacerbations.²²⁴ In both seasonal and perennial allergic asthma, AIT effectively reduced the risk of exacerbations and lower respiratory tract infections.²²⁵ Clinical benefits have also been confirmed with pollen allergen extracts (both SCIT and SLIT).¹² Similar results were reported by REACT (real-world effectiveness in AIT) study, where in addition to the decrease in asthma treatment and severe asthma exacerbations in the AIT group, reductions in pneumonia with antibiotic prescriptions, hospitalizations and duration of inpatients stays were all in favour of AIT.¹⁰⁹ Studies of prescription databases in Europe indicate that AIT is effective in the treatment and management of asthma, outperforming groups that received only anti-asthmatic medication. Furthermore, birch pollen AIT has proven its long-term effectiveness, reducing AR and asthma medication intake up to 6 years post-treatment.²²¹ Asthma patients in the AIT group also had higher rates of complete drug reduction.²²² Additionally, the cost-effectiveness of AIT for allergic asthma, particularly SCIT,

has been demonstrated, which may influence future policy decisions and prescribing habits. Even when accounting for allergic rhinitis as a comorbidity, SCIT remained cost-effective. As such, the studies support the wider use of AIT, and particularly SCIT, in the management of allergic asthma.¹⁶⁹

Identifying the right patient for AIT is crucial.²²⁶ Research suggests that polysensitized patients with allergic rhinitis and class 2–4 asthma, according to the Global Initiative for Asthma (GINA) guidelines, as well as those with a high eosinophilic response, are likely good responders to AIT.¹³ After successful trials with HDM-SLIT tablets, current guidelines recommend AIT for patients with controlled or partially controlled HDM allergic asthma.²²⁷ Using a biologic can improve asthma control and may allow more patients to be eligible for AIT.

10 | CHALLENGES, GAPS AND FUTURE DIRECTIONS

The primary advantage of AIT is its long-term disease-modifying effect. Among numerous challenges and gaps, the need for a more personalized and precision-driven approach to patient stratification and AIT management is crucial. It is necessary to refine phenotyping and endotyping using mHealth, molecular allergy diagnosis and comprehensive immune biomarker assessments. These tools can contribute significantly to both prospective and retrospective patient stratification, offering greater precision and optimizing therapeutics (theratypes). Additionally, it is crucial to focus on the development of innovative AIT preparations that are not only more effective but also safer and more convenient for patients. Combining AIT with biological therapeutics has shown great promise, and broadening its application may help improve patient compliance by reducing therapy-associated risks, duration and costs. The limited resources in the healthcare system present a challenge, especially concerning costs. Nonetheless, increased awareness among patients and payers about AIT's preventive effect on limiting allergic disease and asthma development or exacerbation should help address this challenge.

The progress is inherently connected to the methodology we utilize for clinical research. As these studies are resource-demanding, methodological enhancements are crucial to preserving resources and simultaneously producing high-quality evidence that meets regulatory requirements. This evidence is often gathered from RCTs and RWE. Dealing with the vast amount and complexity of data involved in these processes requires an advanced management approach. Here, AI can play an indispensable role by assisting with the processing of large datasets and generating meaningful insights from them.

In order to address the challenges and gaps in the field, we must focus on utilizing and advancing novel patient enrolment strategies, improving the methodologies for clinical research and further developing our approach to advanced data management. By harnessing the potential of mobile health, biomarkers, molecular diagnosis, big data, and artificial intelligence, we can make significant strides in personalizing and improving AIT for allergic patients. Future efforts should also

aim to maximize the pharmacoeconomic benefit, thereby making it a more cost-effective solution for allergy sufferers worldwide.

AUTHOR CONTRIBUTIONS

Conceptualization: M Jutel and M Zemelka-Wiacek. Writing—original draft preparation, reviewing and editing: all the authors. All authors have read and agreed to the published version of the manuscript.

ACKNOWLEDGEMENTS

The publication was supported by the Ministry of Health subvention according to the number SUBZ.A020.22.060 from the IT Simple system of Wroclaw Medical University, Poland. All the figures were created with [BioRender.com](https://www.biorender.com).

FUNDING INFORMATION

The publication was supported by the Ministry of Health subvention according to the number SUBZ.A020.22.060 from the IT Simple system of Wroclaw Medical University, Poland.

CONFLICT OF INTEREST STATEMENT

Magdalena Zemelka-Wiacek reports to be the EAACI Knowledge Hub Deputy Editor. **Ioana Agache** report to be the Allergy Journal Deputy Editor. **Cezmi A. Akdis** has received research grants from the Swiss National Science Foundation, European Union (EU CURE, EU Syn-Air-G), Novartis Research Institutes, (Basel, Switzerland), Stanford University (Redwood City, Calif) and SciBase (Stockholm, Sweden) is the Co-Chair for EAACI Guidelines on Environmental Science in Allergic diseases and Asthma; is on the Advisory Boards of Sanofi/Regeneron (Bern, Switzerland, New York, USA), Stanford University Sean Parker Asthma Allergy Center (CA, USA), Novartis (Basel, Switzerland), Glaxo Smith Kline (Zurich, Switzerland), Bristol-Myers Squibb (New York, USA), Seed Health (Boston, USA) and SciBase (Stockholm, Sweden); and is the Editor-in-Chief of Allergy Journal. **Mubeccel Akdis** has received research grants from Swiss National science Foundation, Bern; research grant from Stanford University; Leading House for the Latin American Region, Seed Money Grant. She is in the Scientific Advisory Board member of Stanford University-Sean Parker Asthma Allergy Center, CA; Advisory Board member of LEO Foundation Skin Immunology Research Center, Copenhagen. **Thomas B. Casale** has received study grants from Aimmune Therapeutics, Genentech, Sanofi, Regeneron, NIH via his institution. He has also consulted for Genentech, Sanofi, Regeneron, Astra Zeneca, and ARS. **Stephanie Dramburg** declares personal fees from Allergopharma, LETI, Bencard/Allergy Therapeutics, DBV Technologies, OMRON Healthcare. **Karina Jahnz-Rózyk** declares Speaker, Conference with Shire, Takeda, Kedrion, CSL Behring, Projects and Advisory Board and personal fees with Shire, Takeda, Abbvie Polska Sp.zoo, AstraZeneca, CSL Behring, Allergopharma&CoKG, Baxter Polska, Baxalta International, Boehringer Ingelheim, Chiesi, BristolMyers Squibb, GSK, Novartis, Pfizer, Teva, Lekam, Sanofi-Pasteur, Sanofi -Aventis, Zentiva, Mylan Healthcare Sp. z o.o./Viatrix. **Anna Kosowska** has

nothing to disclose. **Paolo M. Matricardi** reports grants and personal fees from Euroimmun AG, during the conduct of the study, grants and personal fees from Thermo Fisher Scientific, personal fees from Hycor Biomedical Inc, outside the submitted work. **Oliver Pfaar** reports grants and/or personal fees from ALK-Abelló, Allergopharma, Stallergenes Greer, HAL Allergy Holding B.V./HAL Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics, Lofarma, ASIT Biotech Tools S.A., Laboratorios LETI/LETI Pharma, GlaxoSmithKline, ROXALL Medizin, Novartis, Sanofi-Aventis und Sanofi-Genzyme, Med Update Europe GmbH, streamedup! GmbH, Pohl-Boskamp, Immunotek S.L., John Wiley and Sons, AS, Paul-Martini-Stiftung (PMS), Regeneron Pharmaceuticals Inc., RG Aertzefortbildung, Institut für Disease Management, Springer GmbH, AstraZeneca, IQVIA Commercial, Ingress Health, Wort&Bild Verlag, Verlag ME, Procter&Gamble, ALTAMIRA, Meinhardt Congress GmbH, Deutsche Forschungsgemeinschaft, Thieme, Deutsche AllergieLiga e.V., AeDA, Alfred-Krupp Krankenhaus, Red Maple Trials Inc., Königlich Dänisches Generalkonsulat, Medizinische Hochschule Hannover, ECM Expro&Conference Management, Technische Universität Dresden, Lilly, Paul Ehrlich Institut (PEI), all outside the submitted work and within the last 36 months; and he is member of EAACI Excom, member of ext. board of directors DGAKI; coordinator, main or co-author of different position papers and guidelines in rhinology, allergology and allergen-immunotherapy. **Mohamed H. Shamji** reports grants from Regeneron, Merck, ANGANY Inc, Allergy Therapeutics, and Immune Tolerance Network; reports personal fees from Allergopharma; and reports grants and personal fees from ALK, Allergy Therapeutics, and ANGANY Inc. **Marek Jutel** reports personal fees from ALK-Abello, Allergopharma, Stallergenes, Anergis, Allergy Therapeutics, Leti, HAL, during the conduct of the study; personal fees from GSK, Novartis, Teva, Takeda, Chiesi the submitted work; and is the Allergy Journal Deputy Editor.

DATA AVAILABILITY STATEMENT

Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

ORCID

Magdalena Zemelka-Wiacek  <https://orcid.org/0000-0001-7201-8638>

[org/0000-0001-7201-8638](https://orcid.org/0000-0001-7201-8638)

Ioana Agache  <https://orcid.org/0000-0001-7994-364X>

Cezmi A. Akdis  <https://orcid.org/0000-0001-8020-019X>

Mubeccel Akdis  <https://orcid.org/0000-0003-0554-9943>

Thomas B. Casale  <https://orcid.org/0000-0002-3149-7377>

Stephanie Dramburg  <https://orcid.org/0000-0002-9303-3260>

Karina Jahnz-Rózyk  <https://orcid.org/0000-0002-3505-1858>

Anna Kosowska  <https://orcid.org/0000-0001-8991-0198>

Paolo M. Matricardi  <https://orcid.org/0000-0001-5485-0324>

Oliver Pfaar  <https://orcid.org/0000-0003-4374-9639>

Mohamed H. Shamji  <https://orcid.org/0000-0003-3425-3463>

Marek Jutel  <https://orcid.org/0000-0003-1555-9379>

REFERENCES

1. Noon L. Prophylactic inoculation against hay fever. *Int Arch Allergy Appl Immunol.* 1953;4(4):285-288. doi:10.1159/000228032
2. Pfaar O, Bousquet J, Durham SR, et al. One hundred and ten years of allergen immunotherapy: A journey from empiric observation to evidence. *Allergy.* 2022;77(2):454-468. doi:10.1111/all.15023
3. Muraro A, Roberts G, Halken S, et al. EAACI guidelines on allergen immunotherapy: executive statement. *Allergy.* 2018;73(4):739-743. doi:10.1111/all.13420
4. Dhimi S, Nurmatov U, Arasi S, et al. Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic review and meta-analysis. *Allergy.* 2017;72(11):1597-1631. doi:10.1111/all.13201
5. Roberts G, Pfaar O, Akdis CA, et al. EAACI guidelines on allergen immunotherapy: allergic rhinoconjunctivitis. *Allergy.* 2018;73(4):765-798. doi:10.1111/all.13317
6. Lodge CJ, Waidyatillake N, Peters RL, et al. Efficacy and safety of oral immunotherapy for peanut, cow's milk, and hen's egg allergy: a systematic review of randomized controlled trials. *Clin Transl Allergy.* 2023;13(7):e12268. doi:10.1002/ctt2.12268
7. PALISADE Group of Clinical Investigators, Vickery BP, Vereda A, et al. AR101 oral immunotherapy for Peanut allergy. *N Engl J Med.* 2018;379(21):1991-2001. doi:10.1056/NEJMoa1812856
8. Pongracic JA, Gagnon R, Sussman G, et al. Safety of Epicutaneous immunotherapy in Peanut-allergic children: REALISE randomized clinical trial results. *J Allergy Clin Immunol Pract.* 2022;10(7):1864-1873.e10. doi:10.1016/j.jaip.2021.11.017
9. Senti G, Cramer R, Kuster D, et al. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. *J Allergy Clin Immunol.* 2012;129(5):1290-1296. doi:10.1016/j.jaci.2012.02.026
10. Hoffmann HJ, Hviid-Vyff B. Strengthening the case for intralymphatic immunotherapy. *Curr Opin Allergy Clin Immunol.* 2022;22(6):387-395. doi:10.1097/ACI.0000000000000857
11. Greenhawt M, Sindher SB, Wang J, et al. Phase 3 trial of Epicutaneous immunotherapy in toddlers with Peanut allergy. *N Engl J Med.* 2023;388(19):1755-1766. doi:10.1056/NEJMoa2212895
12. Diamant Z, van Maaren M, Muraro A, Jesenak M, Striz I. Allergen immunotherapy for allergic asthma: the future seems bright. *Respir Med.* 2023;210:107125. doi:10.1016/j.rmed.2023.107125
13. de Blay F, Gherasim A, Casale TB, Doyen V, Bernstein D. Which patients with asthma are most likely to benefit from allergen immunotherapy? *J Allergy Clin Immunol.* 2022;149(3):833-843. doi:10.1016/j.jaci.2022.01.011
14. Hesse L, Oude Elberink JNG, van Oosterhout AJM, Nawijn MC. Allergen immunotherapy for allergic airway diseases: use lessons from the past to design a brighter future. *Pharmacol Ther.* 2022;237:108115. doi:10.1016/j.pharmthera.2022.108115
15. Sahiner UM, Giovannini M, Escribese MM, et al. Mechanisms of allergen immunotherapy and potential biomarkers for clinical evaluation. *J Pers Med.* 2023;13(5):845. doi:10.3390/jpm13050845
16. Accessed September 30, 2023. <https://hub.eaaci.org/resources/guidelines/>
17. Accessed September 30, 2023. <https://www.nestle.com/media/pressreleases/allpressreleases/european-commission-approves-aimmune-palforzia>
18. Akdis M. Healthy immune response to allergens: T regulatory cells and more. *Curr Opin Immunol.* 2006;18(6):738-744. doi:10.1016/j.coi.2006.06.003
19. Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. *N Engl J Med.* 1999;341(7):468-475. doi:10.1056/NEJM199908123410702
20. Kim YW, Tonti E, Hickey P, et al. Immunological changes in peripheral blood following nasal allergen challenge in subjects with allergic rhinitis pre- and post-peptide immunotherapy: an open-label clinical study. *Allergy.* 2021;76(6):1907-1911. doi:10.1111/all.14710
21. Wang SH, Zissler UM, Buettner M, et al. An exhausted phenotype of TH 2 cells is primed by allergen exposure, but not reinforced by allergen-specific immunotherapy. *Allergy.* 2021;76(9):2827-2839. doi:10.1111/all.14896
22. Möller C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). *J Allergy Clin Immunol.* 2002;109(2):251-256. doi:10.1067/mai.2002.121317
23. Burks AW, Calderon MA, Casale T, et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European academy of allergy and clinical immunology/PRACTALL consensus report. *J Allergy Clin Immunol.* 2013 May;131(5):1288-1296.e3. doi:10.1016/j.jaci.2013.01.049
24. Creticos PS, Maloney J, Bernstein DI, et al. Randomized controlled trial of a ragweed allergy immunotherapy tablet in north American and European adults. *J Allergy Clin Immunol.* 2013;131(5):1342-1349.e6. doi:10.1016/j.jaci.2013.03.019
25. van Zelm MC, McKenzie CI, Varese N, Rolland JM, O'Hehir RE. Advances in allergen-specific immune cell measurements for improved detection of allergic sensitization and immunotherapy responses. *Allergy.* 2021;76(11):3374-3382. doi:10.1111/all.15036
26. López JF, Bel Imam M, Satitsuksanoa P, et al. Mechanisms and biomarkers of successful allergen-specific immunotherapy. *Asia Pac Allergy.* 2022;12(4):e45. doi:10.5415/apallergy.2022.12.e45
27. Durham SR, Till SJ. Immunologic changes associated with allergen immunotherapy. *J Allergy Clin Immunol.* 1998;102(2):157-164. doi:10.1016/s0091-6749(98)70079-x
28. Akdis CA, Akdis M. Mechanisms and treatment of allergic disease in the big picture of regulatory T cells. *J Allergy Clin Immunol.* 2009;123(4):735-746; quiz 747-8. doi:10.1016/j.jaci.2009.02.030
29. Akdis CA, Blesken T, Akdis M, Wüthrich B, Blaser K. Role of interleukin 10 in specific immunotherapy. *J Clin Invest.* 1998;102(1):98-106. doi:10.1172/JCI2250
30. Jutel M, Akdis M, Budak F, et al. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. *Eur J Immunol.* 2003;33(5):1205-1214. doi:10.1002/eji.200322919
31. Akdis CA, Akdis M, Blesken T, et al. Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. *J Clin Invest.* 1996;98(7):1676-1683. doi:10.1172/JCI118963
32. Larché M, Wraith DC. Peptide-based therapeutic vaccines for allergic and autoimmune diseases. *Nat Med.* 2005;11(4 Suppl):S69-S76. doi:10.1038/nm1226
33. Francis JN, Till SJ, Durham SR. Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. *J Allergy Clin Immunol.* 2003;111(6):1255-1261. doi:10.1067/mai.2003.1570
34. Meiler F, Zumkehr J, Klunker S, Rückert B, Akdis CA, Akdis M. In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure. *J Exp Med.* 2008;205(12):2887-2898. doi:10.1084/jem.20080193
35. Radulovic S, Jacobson MR, Durham SR, Nouri-Aria KT. Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. *J Allergy Clin Immunol.* 2008;121(6):1467-1472.e1. doi:10.1016/j.jaci.2008.03.013
36. Ling EM, Smith T, Nguyen XD, et al. Relation of CD4+CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. *Lancet.* 2004;363(9409):608-615. doi:10.1016/S0140-6736(04)15592-X
37. Aslam A, Chan H, Warrell DA, Misbah S, Ogg GS. Tracking antigen-specific T-cells during clinical tolerance induction in humans. *PLoS ONE.* 2010;5(6):e11028. doi:10.1371/journal.pone.0011028

38. Van Overtvelt L, Wambre E, Maillère B, et al. Assessment of bet v 1-specific CD4+ T cell responses in allergic and nonallergic individuals using MHC class II peptide tetramers. *J Immunol*. 2008;180(7):4514-4522. doi:10.4049/jimmunol.180.7.4514
39. van de Veen W, Stanic B, Yaman G, et al. IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses. *J Allergy Clin Immunol*. 2013;131:1204-1212.
40. Stanic B, van de Veen W, Wirz OF, et al. IL-10-overexpressing B cells regulate innate and adaptive immune responses. *J Allergy Clin Immunol*. 2015;135(3):771-780.e8. doi:10.1016/j.jaci.2014.07.041
41. Bussmann C, Xia J, Allam JP, Maintz L, Bieber T, Novak N. Early markers for protective mechanisms during rush venom immunotherapy. *Allergy*. 2010;65(12):1558-1565. doi:10.1111/j.1398-9995.2010.02430.x
42. Schmid JM, Würtzen PA, Dahl R, Hoffmann HJ. Early improvement in basophil sensitivity predicts symptom relief with grass pollen immunotherapy. *J Allergy Clin Immunol*. 2014;134(3):741-744.e5. doi:10.1016/j.jaci.2014.04.029
43. Shamji MH, Layhadi JA, Scadding GW, et al. Basophil expression of diamine oxidase: a novel biomarker of allergen immunotherapy response. *J Allergy Clin Immunol*. 2015;135(4):913-921.e9. doi:10.1016/j.jaci.2014.09.049
44. Bartemes KR, Kephart GM, Fox SJ, Kita H. Enhanced innate type 2 immune response in peripheral blood from patients with asthma. *J Allergy Clin Immunol*. 2014;134(3):671-678.e4. doi:10.1016/j.jaci.2014.06.024
45. Sahiner UM, Layhadi JA, Golebski K, et al. Innate lymphoid cells: the missing part of a puzzle in food allergy. *Allergy*. 2021;76(7):2002-2016. doi:10.1111/all.14776
46. Lao-Araya M, Steveling E, Scadding GW, Durham SR, Shamji MH. Seasonal increases in peripheral innate lymphoid type 2 cells are inhibited by subcutaneous grass pollen immunotherapy. *J Allergy Clin Immunol*. 2014;134(5):1193-1195.e4. doi:10.1016/j.jaci.2014.07.029
47. Morita H, Kubo T, Rückert B, et al. Induction of human regulatory innate lymphoid cells from group 2 innate lymphoid cells by retinoic acid. *J Allergy Clin Immunol*. 2019;143(6):2190-2201.e9. doi:10.1016/j.jaci.2018.12.1018
48. Van Ree R, Van Leeuwen WA, Dieges PH, et al. Measurement of IgE antibodies against purified grass pollen allergens (lol p 1, 2, 3 and 5) during immunotherapy. *Clin Exp Allergy*. 1997;27(1):68-74. doi:10.1046/j.1365-2222.1997.d01-416.x
49. Gleich GJ, Zimmermann EM, Henderson LL, Yunginger JW. Effect of immunotherapy on immunoglobulin E and immunoglobulin G antibodies to ragweed antigens: a six-year prospective study. *J Allergy Clin Immunol*. 1982;70(4):261-271. doi:10.1016/0091-6749(82)90062-8
50. Meiler F, Klunker S, Zimmermann M, Akdis CA, Akdis M. Distinct regulation of IgE, IgG4 and IgA by T regulatory cells and toll-like receptors. *Allergy*. 2008;63(11):1455-1463. doi:10.1111/j.1398-9995.2008.01774.x
51. Bordas-Le Floch V, Berjont N, Batard T, et al. Coordinated IgG2 and IgE responses as a marker of allergen immunotherapy efficacy. *Allergy*. 2022;77(4):1263-1273. doi:10.1111/all.15107
52. Aalberse RC, Schuurman J. IgG4 breaking the rules. *Immunology*. 2002;105(1):9-19. doi:10.1046/j.0019-2805.2001.01341.x
53. van der Neut KM, Schuurman J, Losen M, et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic fab arm exchange. *Science*. 2007;317(5844):1554-1557. doi:10.1126/science.1144603
54. Shamji MH, Larson D, Eifan A, et al. Differential induction of allergen-specific IgA responses following timothy grass subcutaneous and sublingual immunotherapy. *J Allergy Clin Immunol*. 2021;148(4):1061-1071.e11. doi:10.1016/j.jaci.2021.03.030
55. Yao Y, Chen CL, Yu D, Liu Z. Roles of follicular helper and regulatory T cells in allergic diseases and allergen immunotherapy. *Allergy*. 2021;76(2):456-470. doi:10.1111/all.14639
56. Incorvaia C, Ridolo E, Bagnasco D, Scurati S, Canonica GW. Personalized medicine and allergen immunotherapy: the beginning of a new era? *Clin Mol Allergy*. 2021;19(1):10. doi:10.1186/s12948-021-00150-z
57. Ogulur I, Pat Y, Ardicli O, et al. Advances and highlights in biomarkers of allergic diseases. *Allergy*. 2021;76(12):3659-3686. doi:10.1111/all.15089
58. Barone SM, Paul AG, Muehling LM, et al. Unsupervised machine learning reveals key immune cell subsets in COVID-19, rhinovirus infection, and cancer therapy. *Elife*. 2021;10:e64653. doi:10.7554/eLife.64653
59. Klueber J, Czolk R, Codreanu-Morel F, et al. High-dimensional immune profiles correlate with phenotypes of peanut allergy during food-allergic reactions. *Allergy*. 2023;78(4):1020-1035. doi:10.1111/all.15408
60. Schmid JM, Würtzen PA, Siddhuraj P, et al. Basophil sensitivity reflects long-term clinical outcome of subcutaneous immunotherapy in grass pollen-allergic patients. *Allergy*. 2021;76(5):1528-1538. doi:10.1111/all.14264
61. Boonpiyathad T, Tantilipikorn P, Ruxrungtham K, et al. IL-10-producing innate lymphoid cells increased in patients with house dust mite allergic rhinitis following immunotherapy. *J Allergy Clin Immunol*. 2021;147(4):1507-1510.e8. doi:10.1016/j.jaci.2020.10.029
62. Golebski K, Layhadi JA, Sahiner U, et al. Induction of IL-10-producing type 2 innate lymphoid cells by allergen immunotherapy is associated with clinical response. *Immunity*. 2021;54(2):291-307. e7. doi:10.1016/j.immuni.2020.12.013
63. McKenzie CI, Varese N, Aui PM, et al. RNA sequencing of single allergen-specific memory B cells after grass pollen immunotherapy: two unique cell fates and CD29 as a biomarker for treatment effect. *Allergy*. 2023;78(3):822-835. doi:10.1111/all.15529
64. Tian GX, Peng KP, Liu MH, et al. CD38+ B cells affect immunotherapy for allergic rhinitis. *J Allergy Clin Immunol*. 2022;149(5):1691-1701.e9. doi:10.1016/j.jaci.2022.01.012
65. Shamji MH, Larson D, Eifan A, et al. Differential induction of allergen-specific IgA responses following timothy grass subcutaneous and sublingual immunotherapy. *J Allergy Clin Immunol*. 2021;148(4):1061-1071.e11. doi:10.1016/j.jaci.2021.03.030
66. Zbären N, Brigger D, Bachmann D, et al. A novel functional mast cell assay for the detection of allergies. *J Allergy Clin Immunol*. 2022;149(3):1018-1030.e11. doi:10.1016/j.jaci.2021.08.006
67. Zheng P, Bian X, Zhai Y, et al. Metabolomics reveals a correlation between hydroxyeicosatetraenoic acids and allergic asthma: evidence from three years' immunotherapy. *Pediatr Allergy Immunol*. 2021;32(8):1654-1662. doi:10.1111/pai.13569
68. Zheng P, Yan G, Zhang Y, et al. Metabolomics reveals process of allergic rhinitis patients with single- and double-species mite subcutaneous immunotherapy. *Metabolites*. 2021;11(9):613. doi:10.3390/metabo11090613
69. Gajdanowicz P, Van Elst D, Smolińska S, et al. The frequency of CD4+ CD25+ FoxP3+ CD127- cells in bet v 1 contiguous overlapping peptide immunotherapy as a putative marker of efficacy. *Allergy*. 2020;75(10):2685-2686. doi:10.1111/all.14342
70. Berin MC, Agashe C, Burks AW, et al. Allergen-specific T cells and clinical features of food allergy: lessons from CoFAR immunotherapy cohorts. *J Allergy Clin Immunol*. 2022;149(4):1373-1382.e12. doi:10.1016/j.jaci.2021.09.029
71. Hoshino M, Akitsu K, Kubota K, Ohtawa J. Serum Periostin as a biomarker for predicting clinical response to house dust mite sublingual immunotherapy in allergic rhinitis. *J Allergy Clin Immunol Pract*. 2021;9(5):1864-1870. doi:10.1016/j.jaip.2020.11.046

72. Matricardi PM, Dramburg S, Alvarez-Perea A, et al. The role of mobile health technologies in allergy care: an EAACI position paper. *Allergy*. 2020;75(2):259-272. doi:10.1111/all.13953
73. Bousquet J, Jutel M, Pfaar O, et al. The role of mobile health technologies in stratifying patients for AIT and its cessation: the ARIA-EAACI perspective. *J Allergy Clin Immunol Pract*. 2021;9(5):1805-1812. doi:10.1016/j.jaip.2021.02.035
74. Tripodi S, Giannone A, Sfika I, et al. Digital technologies for an improved management of respiratory allergic diseases: 10 years of clinical studies using an online platform for patients and physicians. *Ital J Pediatr*. 2020;46(1):105. doi:10.1186/s13052-020-00870-z
75. Linngrün S, Scheumann J, Werchan B, Wildner D, Heilmann T, Bergmann KC. Erratum zu: Die "Husteblume" der Techniker Krankenkasse: erste evaluierte App für Patienten mit allergischer Rhinokonjunktivitis und allergischem Asthma durch Pollen. *Allergo J*. 2021;30:39. doi:10.1007/s15007-021-4914-6
76. Bianchi A, Tsilochristou O, Gabrielli F, Tripodi S, Matricardi PM. The smartphone: a novel diagnostic tool in pollen allergy? *J Investig Allergol Clin Immunol*. 2016;26(3):204-207. doi:10.18176/jiaci.0060
77. Dramburg S, Perna S, Di Fraia M, et al. Prospective (e-diary) vs retrospective (ARIA) measures of severity in allergic rhinoconjunctivitis: an observational compatibility study. *Allergy*. 2023;78(2):550-553. doi:10.1111/all.15499
78. Bédard A, Basagaña X, Anto JM, et al. Treatment of allergic rhinitis during and outside the pollen season using mobile technology. A MASK study. *Clin Transl Allergy*. 2020;10(1):62. doi:10.1186/s13601-020-00342-x Erratum in: *Clin Transl Allergy* 2022 Mar;12(3):e12126.
79. Arasi S, Castelli S, Di Fraia M, et al. @IT2020: an innovative algorithm for allergen immunotherapy prescription in seasonal allergic rhinitis. *Clin Exp Allergy*. 2021;51(6):821-828. doi:10.1111/cea.13867
80. Di Fraia M, Tripodi S, Arasi S, et al. Adherence to prescribed E-diary recording by patients with seasonal allergic rhinitis: observational study. *J Med Internet Res*. 2020;22(3):e16642. doi:10.2196/16642
81. Pizzulli A, Perna S, Florack J, et al. The impact of telemonitoring on adherence to nasal corticosteroid treatment in children with seasonal allergic rhinoconjunctivitis. *Clin Exp Allergy*. 2014;44(10):1246-1254. doi:10.1111/cea.12386
82. Barber D, Diaz-Perales A, Escribese MM, et al. Molecular allergology and its impact in specific allergy diagnosis and therapy. *Allergy*. 2021;76(12):3642-3658. doi:10.1111/all.14969
83. Stringari G, Tripodi S, Caffarelli C, et al. Italian pediatric allergy network (I-PAN). The effect of component-resolved diagnosis on specific immunotherapy prescription in children with hay fever. *J Allergy Clin Immunol*. 2014;134(1):75-81. doi:10.1016/j.jaci.2014.01.042
84. Tripodi S, Frediani T, Lucarelli S, et al. Molecular profiles of IgE to Phleum pratense in children with grass pollen allergy: implications for specific immunotherapy. *J Allergy Clin Immunol*. 2012;129(3):834-839.e8. doi:10.1016/j.jaci.2011.10.045
85. Rodríguez-Domínguez A, Berings M, Rohrbach A, et al. Molecular profiling of allergen-specific antibody responses may enhance success of specific immunotherapy. *J Allergy Clin Immunol*. 2020;146(5):1097-1108. doi:10.1016/j.jaci.2020.03.029
86. Potapova E, Bordas-Le Floch V, Schleder T, et al. Molecular reactivity profiling upon immunotherapy with a 300 IR sublingual house dust mite tablet reveals marked humoral changes towards major allergens. *Allergy*. 2022;77(10):3084-3095. doi:10.1111/all.15327
87. Forchert L, Potapova E, Panetta V, et al. Der p 23-specific IgE response throughout childhood and its association with allergic disease: a birth cohort study. *Pediatr Allergy Immunol*. 2022;33(7):e13829. doi:10.1111/pai.13829
88. Cipriani F, Mastrorilli C, Tripodi S, et al. Italian pediatric allergy network (I-PAN). Diagnostic relevance of IgE sensitization profiles to eight recombinant Phleum pratense molecules. *Allergy*. 2018;73(3):673-682. doi:10.1111/all.13338
89. Jacobsen L, Niggemann B, Dreborg S, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. *Allergy*. 2007;62(8):943-948. doi:10.1111/j.1398-9995.2007.01451.x
90. Dramburg S, Hilger C, Santos AF, et al. EAACI molecular allergology User's guide 2.0. *Pediatr Allergy Immunol*. 2023;34(Suppl 28):e13854. doi:10.1111/pai.13854
91. Fountzilias E, Tsimberidou AM, Vo HH, Kurzrock R. Clinical trial design in the era of precision medicine. *Genome Med*. 2022;14(1):101. doi:10.1186/s13073-022-01102-1
92. FDA. Guideline "adaptive design clinical trials for drugs and biologics guidance for industry". 2019 Accessed July 19, 2023. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/adaptive-design-clinical-trials-drugs-and-biologics-guidance-industry>
93. EMA. Reflection paper in methodological issues in confirmatory clinical trial planned with an adaptive design. 2007 Accessed July 19, 2023. https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-methodological-issues-confirmatory-clinical-trials-planned-adaptive-design_en.pdf
94. Woodcock J, LaVange LM. Master protocols to study multiple therapies, multiple diseases, or both. *N Engl J Med*. 2017;377(1):62-70. doi:10.1056/NEJMr1510062
95. Bauer P, Bretz F, Dragalin V, König F, Wassmer G. Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls. *Stat Med*. 2016;35(3):325-347. doi:10.1002/sim.6472
96. Tang X, Rabin RL, Yan LK. A three-stage design for allergen immunotherapy trials. *Allergy*. 2022;77(6):1835-1842. doi:10.1111/all.15117
97. Eichler HG, Sweeney F. The evolution of clinical trials: can we address the challenges of the future? *Clin Trials*. 2018;15(1_suppl):27-32. doi:10.1177/1740774518755058
98. Sousa-Pinto B, Pfaar O, Bousquet J. Real-life evidence in allergen immunotherapy: moving forward with mHealth apps. *Allergol Select*. 2023;7:47-56. doi:10.5414/ALX02343E
99. Fritzsche B, Contoli M, Porsbjerg C, Buchs S, Larsen JR, Freemantle N. Real-world evidence: methods for assessing long-term health and effectiveness of allergy immunotherapy. *J Allergy Clin Immunol*. 2022;149(3):881-883. doi:10.1016/j.jaci.2021.12.781
100. Paoletti G, Di Bona D, Chu DK, et al. Allergen immunotherapy: the growing role of observational and randomized trial "real-world evidence". *Allergy*. 2021;76(9):2663-2672. doi:10.1111/all.14773
101. Khosla S, White R, Medina J, et al. Real world evidence (RWE) – a disruptive innovation or the quiet evolution of medical evidence generation? *F1000Res*. 2018;7:111. doi:10.12688/f1000research.13585.2
102. Khan S, Krishna MT, Michaelis LJ, et al. BSACI registry for immunotherapy (BRIT): providing safe and effective immunotherapy for allergies and urticaria. *Clin Exp Allergy*. 2021;51(8):985-988. doi:10.1111/cea.13887
103. Ibáñez-Sandín MD, Escudero C, Candón Morillo R, et al. Oral immunotherapy in severe cow's milk allergic patients treated with omalizumab: real life survey from a Spanish registry. *Pediatr Allergy Immunol*. 2021;32(6):1287-1295. doi:10.1111/pai.13517
104. Borg M, Løkke A, Hilberg O. Geographical and socioeconomic differences in compliance with and access to allergen immunotherapy in Denmark: a nationwide registry-based study – 1998–2016. *Respir Med*. 2021;178:106332. doi:10.1016/j.rmed.2021.106332
105. Vogelberg C, Klimek L, Brüggjenjürgen B, Jutel M. Real-world evidence for the long-term effect of allergen immunotherapy:

- current status on database-derived European studies. *Allergy*. 2022;77(12):3584-3592. doi:10.1111/all.15506
106. Passalacqua G, Bagnasco D. Real-life studies in allergen immunotherapy. *Curr Opin Allergy Clin Immunol*. 2021;21(4):361-367. doi:10.1097/ACI.0000000000000757
 107. Bozek A, Cudak A, Walter CG. Long-term efficacy of injected allergen immunotherapy for treatment of grass pollen allergy in elderly patients with allergic rhinitis. *Allergy Asthma Proc*. 2020;41(4):271-277. doi:10.2500/aap.2020.41.200035
 108. Valovirta E, Petersen TH, Piotrowska T, et al. Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy. *J Allergy Clin Immunol*. 2018;141(2):529-538.e13. doi:10.1016/j.jaci.2017.06.014
 109. Fritzsching B, Contoli M, Porsbjerg C, et al. Long-term real-world effectiveness of allergy immunotherapy in patients with allergic rhinitis and asthma: results from the REACT study, a retrospective cohort study. *Lancet Reg Health Eur*. 2021;13:100275. doi:10.1016/j.lanep.2021.100275
 110. Park M, Kapoor S, Yi J, Hura N, Lin SY. Sublingual immunotherapy persistence and adherence in real-world settings: a systematic review. *Int Forum Allergy Rhinol*. 2023;13(5):924-941. doi:10.1002/alr.23086
 111. Park MJ, Kapoor S, Yi J, Hura N, Lin SY. Systematic review of real-world persistence and adherence in subcutaneous allergen immunotherapy. *Int Forum Allergy Rhinol*. 2023;13(3):255-264. doi:10.1002/alr.23078
 112. Brüggjenjürgen B, Reinhold T. Cost-effectiveness of grass pollen subcutaneous immunotherapy (SCIT) compared to sublingual immunotherapy (SLIT) and symptomatic treatment in Austria, Spain, and Switzerland. *J Med Econ*. 2018;21(4):374-381. doi:10.1080/13696998.2017.1419959
 113. Brüggjenjürgen B, Klimek L, Reinhold T. Real world effectiveness and cost consequences of grass pollen SCIT compared with SLIT and symptomatic treatment. *Allergo J Int*. 2021;30(6):198-206.
 114. Di Bona D, Bilancia M, Albanesi M, Caiaffa MF, Macchia L. Cost-effectiveness of grass pollen allergen immunotherapy in adults. *Allergy*. 2020;75(9):2319-2329. doi:10.1111/all.14246
 115. European Medicines Agency. Committee for medicinal products for human use (CHMP): Guideline on the Clinical Development of Products for Specific Immunotherapy for The Treatment of Allergic Diseases (CHMP/EWP/18504/2006). 2008 Accessed July 19, 2023. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003605.pdf
 116. European Medicines Agency; Committee for Medicinal Products for Human Use (CHMP). Guideline on allergen products: production and quality issues. EMEA/CHMP/BWP/304831/2007. London. November 20, 2008. Accessed July 19, 2023. www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003333.pdf
 117. Hoffmann HJ, Valovirta E, Pfaar O, et al. Novel approaches and perspectives in allergen immunotherapy. *Allergy*. 2017;72(7):1022-1034. doi:10.1111/all.13135
 118. Pfaar O, Alvaro M, Cardona V, Hamelmann E, Mösges R, Kleine-Tebbe J. Clinical trials in allergen immunotherapy: current concepts and future needs. *Allergy*. 2018;73(9):1775-1783. doi:10.1111/all.13429
 119. Pfaar O, Bonini S, Cardona V, et al. Perspectives in allergen immunotherapy: 2017 and beyond. *Allergy*. 2018;73(Suppl 104):5-23. doi:10.1111/all.13355
 120. Pfaar O, Demoly P, van Wijk RG, et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI position paper. *Allergy*. 2014;69(7):854-867. doi:10.1111/all.12383
 121. Sousa-Pinto B, Azevedo LF, Jutel M, et al. Development and validation of combined symptom-medication scores for allergic rhinitis. *Allergy*. 2022;77(7):2147-2162. doi:10.1111/all.15199
 122. Bousquet J, Pfaar O, Togias A, et al. 2019 ARIA Care pathways for allergen immunotherapy. *Allergy*. 2019;74(11):2087-2102. doi:10.1111/all.13805
 123. Bahbah F, Gentil C, Sousa-Pinto B, et al. Patient-reported outcome measures in birch pollen allergic patients treated with sublingual immunotherapy reflect real life. *Allergy*. 2023;78(4):1113-1116. doi:10.1111/all.15550
 124. Wedi B, Wiczorek D, Kapp A. Placeboeffekt in Studien zur allergenspezifischen Immuntherapie mit Inhalationsallergenen [Placebo effect in clinical trials with allergen-specific immunotherapy with inhaled allergens]. *Hautarzt*. 2017;68(4):297-306. German. doi:10.1007/s00105-017-3937-0
 125. Pfaar O, Agache I, Bergmann KC, et al. Placebo effects in allergen immunotherapy-an EAACI task force position paper. *Allergy*. 2021;76(3):629-647. doi:10.1111/all.14331
 126. Circassia Pharmaceuticals Inc. Circassia announces top-line results from cat allergy phase III study [Internet]. 2016 Accessed July 19, 2023. <https://investors.niox.com/media/press-releases/circassia-announces-top-line-results-from-cat-allergy-phase-iii-study/>
 127. Zieglmayer PU, Pfaar O. Update on the use of allergen challenge chambers in immunotherapy: clinical implications. *Curr Opin Allergy Clin Immunol*. 2022;22(2):132-136. doi:10.1097/ACI.0000000000000808
 128. Rösner-Friese K, Kaul S, Vieths S, Pfaar O. Environmental exposure chambers in allergen immunotherapy trials: current status and clinical validation needs. *J Allergy Clin Immunol*. 2015;135(3):636-643. doi:10.1016/j.jaci.2014.10.045
 129. Pfaar O, Calderon MA, Andrews CP, et al. Allergen exposure chambers: harmonizing current concepts and projecting the needs for the future – an EAACI position paper. *Allergy*. 2017;72(7):1035-1042. doi:10.1111/all.13133
 130. Zemelka-Wiacek M, Kosowska A, Winiarska E, Sobanska E, Jutel M. Validated allergen exposure chamber is plausible tool for the assessment of house dust mite-triggered allergic rhinitis. *Allergy*. 2023;78(1):168-177. doi:10.1111/all.15485
 131. Pfaar O, Bergmann KC, Bonini S, et al. Technical standards in allergen exposure chambers worldwide – an EAACI task force report. *Allergy*. 2021;76(12):3589-3612. doi:10.1111/all.14957
 132. Radzikowska U, Baerenfaller K, Cornejo-Garcia JA, et al. Omics technologies in allergy and asthma research: an EAACI position paper. *Allergy*. 2022;77(10):2888-2908. doi:10.1111/all.15412
 133. Kim M, Tagkopoulou I. Data integration and predictive modeling methods for multi-omics datasets. *Mol Omics*. 2018;14(1):8-25. doi:10.1039/c7mo00051k
 134. Proper SP, Azouz NP, Mersha TB. Achieving precision medicine in allergic disease: progress and challenges. *Front Immunol*. 2021;12:720746. doi:10.3389/fimmu.2021.720746
 135. López de Maturana E, Alonso L, Alarcón P, et al. Challenges in the integration of omics and non-omics data. *Genes (Basel)*. 2019;10(3):238. doi:10.3390/genes10030238
 136. Gautam Y, Johansson E, Mersha TB. Multi-omics profiling approach to asthma: an evolving paradigm. *J Pers Med*. 2022;12(1):66. doi:10.3390/jpm12010066
 137. Mikkelsen JG, Sørensen NL, Merrild CH, Jensen MB, Thomsen JL. Patient perspectives on data sharing regarding implementing and using artificial intelligence in general practice – a qualitative study. *BMC Health Serv Res*. 2023;23(1):335. doi:10.1186/s12913-023-09324-8
 138. Mintz Y, Brodie R. Introduction to artificial intelligence in medicine. *Minim Invasive Ther Allied Technol*. 2019;28:73-81.
 139. Jutel M, Zemelka-Wiacek M, Ordak M, et al. The artificial intelligence (AI) revolution: how important for scientific work and its reliable sharing. *Allergy*. 2023;78:2085-2088. doi:10.1111/all.15778
 140. MacMath D, Chen M, Khoury P. Artificial intelligence: exploring the future of innovation in allergy immunology. *Curr Allergy Asthma Rep*. 2023;23(6):351-362. doi:10.1007/s11882-023-01084-z

141. Lee B, Zhang S, Poleksic A, Xie L. Heterogeneous multi-layered network model for omics data integration and analysis. *Front Genet.* 2020;10:1381. doi:10.3389/fgene.2019.01381
142. Olsson O, Karlsson M, Persson AS, et al. Efficient, automated and robust pollen analysis using deep learning. *Methods Ecol Evol.* 2021;12(5):850-862. doi:10.1111/2041-210X.13575
143. Kamangir H, Collins W, Tissot P, King A. A deep-learning model to predict thunderstorms within 400 km² South Texas domains. *Meteorol Appl.* 2020;27:e1905. doi:10.1002/met.1905
144. Abbaspour S, Robbins GK, Blumenthal KG, et al. Identifying modifiable predictors of COVID-19 vaccine side effects: a machine learning approach. *Vaccines (Basel).* 2022;10(10):1747. doi:10.3390/vaccines10101747
145. Bates DW, Levine D, Syrowatka A, et al. The potential of artificial intelligence to improve patient safety: a scoping review. *NPJ Digit Med.* 2021;4(1):54. doi:10.1038/s41746-021-00423-6
146. Suprun M, Sicherer SH, Wood RA, et al. Early epitope-specific IgE antibodies are predictive of childhood peanut allergy. *J Allergy Clin Immunol.* 2020;146(5):1080-1088. doi:10.1016/j.jaci.2020.08.005
147. Kuniyoshi Y, Tokutake H, Takahashi N, Kamura A, Yasuda S, Tashiro M. Machine learning approach and oral food challenge with heated egg. *Pediatr Allergy Immunol.* 2021;32(4):776-778. doi:10.1111/pai.13433
148. Randhawa IS, Groshenkov K, Sigalov G. Food anaphylaxis diagnostic marker compilation in machine learning design and validation. *PLoS ONE.* 2023;18(4):e0283141. doi:10.1371/journal.pone.0283141
149. Suárez-Fariñas M, Suprun M, Chang HL, et al. Predicting development of sustained unresponsiveness to milk oral immunotherapy using epitope-specific antibody binding profiles. *J Allergy Clin Immunol.* 2019;143(3):1038-1046. doi:10.1016/j.jaci.2018.10.028
150. Layhadi J, Lenormand M, Kirtland M, et al. Novel machine learning-led discovery of adjuvant drug candidate for allergen immunotherapy using synthetic toll-like receptor 2/6 agonist. *J Allergy Clin Immunol.* 2022;149:AB71. doi:10.1016/j.jaci.2021.12.260
151. Shamji MH, Ollert M, Adcock IM, et al. EAACI guidelines on environmental science in allergic diseases and asthma – leveraging artificial intelligence and machine learning to develop a causality model in exposomics. *Allergy.* 2023;78:1742-1757. doi:10.1111/all.15667
152. Concept paper on a Guideline for allergen products development in moderate to low-sized study populations. EMA/CHMP/251023/2018 Rheumatology/Immunology Working Party (RIWP) (of 13th December 2018). Accessed July 19, 2023. https://www.ema.europa.eu/en/documents/scientific-guideline/scientific-guideline-concept-paper-guideline-allergen-products-development-moderate-low-sized-study-populations_en.pdf
153. EMA. *European Medicines Agency: Committee on Medicinal Products for Human Use Guideline on the Clinical Development of Products for Specific Immunotherapy for the Treatment of Allergic Diseases.* CHMP/EWP/18504/2006. EMA; 2008. Accessed July 19, 2023. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-development-products-specific-immunotherapy-treatment-allergic-diseases_en.pdf
154. Allen-Ramey F, Mao J, Blauer-Peterson C, Rock M, Nathan R, Halpern R. Healthcare costs for allergic rhinitis patients on allergy immunotherapy: a retrospective observational study. *Curr Med Res Opin.* 2017;33(11):2039-2047. doi:10.1080/03007995.2017.1359517
155. Asaria M, Dhani S, van Ree R, et al. Health economic analysis of allergen immunotherapy for the management of allergic rhinitis, asthma, food allergy and venom allergy: a systematic overview. *Allergy.* 2018;73(2):269-283. doi:10.1111/all.13254
156. Augustin M. Sozioökonomische Bedeutung allergischer Erkrankungen. In: Klimek L, Vogelberg C, Werfel T, eds. *Weißbuch Allergie in Deutschland. überarb. und erw. Aufl.* München. Springer Medizin Verlag; 2018:52-60.
157. Böcking C, Renz H, Pfeifferle PI. Prävalenz und sozioökonomische Bedeutung von Allergien in Deutschland [Prevalence and socio-economic relevance of allergies in Germany]. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz.* 2012;55(3):303-307. German. doi:10.1007/s00103-011-1427-6
158. Dierick BJH, van der Molen T, Flokstra-de Blok BMJ, et al. Burden and socioeconomics of asthma, allergic rhinitis, atopic dermatitis and food allergy. *Expert Rev Pharmacoecon Outcomes Res.* 2020;20(5):437-453. doi:10.1080/14737167.2020.1819793
159. Incorvaia C, Agostinis F, Amoroso S, et al. Pharmacoeconomics of subcutaneous allergen immunotherapy. *Eur Ann Allergy Clin Immunol.* 2007;39: Spec No: 17-20.
160. Jutel M, Agache I, Bonini S, et al. International consensus on allergen immunotherapy II: mechanisms, standardization, and pharmacoeconomics. *J Allergy Clin Immunol.* 2016;137(2):358-368. doi:10.1016/j.jaci.2015.12.1300
161. Lamb CE, Ratner PH, Johnson CE, et al. Economic impact of workplace productivity losses due to allergic rhinitis compared with select medical conditions in the United States from an employer perspective. *Curr Med Res Opin.* 2006;22(6):1203-1210. doi:10.1185/030079906X112552
162. Pfaar O, Ankermann T, Augustin M, et al. Guideline on allergen immunotherapy in IgE-mediated allergic diseases: S2K guideline of the German Society of Allergology and Clinical Immunology (DGAKI), Society of Pediatric Allergology and Environmental Medicine (GPA), medical Association of German Allergologists (AeDA), Austrian Society of Allergology and Immunology (ÖGAI), Swiss Society for Allergology and Immunology (SSAI), German dermatological society (DDG), German Society of Oto-Rhinolaryngology, head and neck surgery (DGHNO-KHC), German Society of Pediatrics and Adolescent Medicine (DGKJ), Society of Pediatric Pulmonology (GPP), German respiratory society (DGP), German professional Association of Otolaryngologists (BVHNO), German Association of Paediatric and Adolescent Care Specialists (BVKJ), Federal Association of Pneumologists, sleep and respiratory physicians (BdP), professional Association of German Dermatologists (BVDD). *Allergol Select.* 2022;6:167-232. doi:10.5414/ALX02331E
163. Bowrin K, Briere JB, Levy P, Millier A, Clay E, Toumi M. Cost-effectiveness analyses using real-world data: an overview of the literature. *J Med Econ.* 2019;22(6):545-553. doi:10.1080/13696998.2019.1588737
164. Cox L. Pharmacoeconomics of allergy immunotherapy versus pharmacotherapy. *Expert Rev Clin Immunol.* 2021;17(3):255-268. doi:10.1080/1744666X.2021.1886079
165. Drummond M, Stoddard G, Torrance G. *Methods for the Economic Evaluation of Health Care Programmes.* Oxford medical Publications; 1987.
166. Meadows A, Kaambwa B, Novielli N, et al. A systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitis. *Health Technol Assess.* 2013;17(27):vi, xi-xiv, 1-322. doi:10.3310/hta17270
167. Bachert C, Noergaard AJ. Cost-effectiveness of immunotherapy in the treatment of seasonal allergic rhinitis: identifying product-specific parameters of relevance for health care decision-makers and clinicians. *Int Arch Allergy Immunol.* 2015;168(3):213-217. doi:10.1159/000443272
168. Ellis AK, Gagnon R, Hammerby E, Lau A. Sublingual immunotherapy tablet for the treatment of house dust mite allergic rhinitis in Canada: an alternative to minimize treatment costs? *Allergy Asthma Clin Immunol.* 2019;15:27. doi:10.1186/s13223-019-0344-3
169. Farraia M, Paciência I, Castro Mendes F, et al. Cost-effectiveness analysis of house dust mite allergen immunotherapy in children

- with allergic asthma. *Allergy*. 2022;77(9):2688-2698. doi:10.1111/all.15321
170. Lombardi C, Melli V, Incorvaia C, Ridolo E. Pharmacoeconomics of sublingual immunotherapy with the 5-grass pollen tablets for seasonal allergic rhinitis. *Clin Mol Allergy*. 2017;15:5. doi:10.1186/s12948-017-0058-3
 171. Ronaldson S, Taylor M, Bech PG, Shenton R, Bufe A. Economic evaluation of SQ-standardized grass allergy immunotherapy tablet (Grazax®) in children. *Clinicoecon Outcomes Res*. 2014;6:187-196. doi:10.2147/CEOR.S44079
 172. Westerhout KY, Verheggen BG, Schreder CH, Augustin M. Cost effectiveness analysis of immunotherapy in patients with grass pollen allergic rhinoconjunctivitis in Germany. *J Med Econ*. 2012;15(5):906-917. doi:10.3111/13696998.2012.688904
 173. Richter AK, Klimek L, Merk HF, et al. Impact of increasing treatment rates on cost-effectiveness of subcutaneous immunotherapy (SCIT) in respiratory allergy: a decision analytic modelling approach. *Eur J Health Econ*. 2018;19(9):1229-1242. doi:10.1007/s10198-018-0970-6
 174. Cox LS, Hankin C, Lockey R. Allergy immunotherapy adherence and delivery route: location does not matter. *J Allergy Clin Immunol Pract*. 2014;2(2):156-160. doi:10.1016/j.jaip.2014.01.010
 175. Farraia M, Paciência I, Castro Mendes F, et al. Cost-effectiveness analysis of house dust mite allergen immunotherapy in children with allergic asthma [published online ahead of print, 2022 Apr 22]. *Allergy*. 2022;77:2698. doi:10.1111/all.15321
 176. Parra-Padilla D, Zakzuk J, Carrasquilla M, et al. Cost-effectiveness of the subcutaneous house dust mite allergen immunotherapy plus pharmacotherapy for allergic asthma: a mathematical model. *Allergy*. 2021;76(7):2229-2233. doi:10.1111/all.14723
 177. Chabot A, Lang C, Kündig TM, Schmid-Grendelmeier P, Johansen P. Potential cost savings by switching from subcutaneous to intralymphatic insect venom immunotherapy. *Int Arch Allergy Immunol*. 2023;184:985-993. doi:10.1159/000531332
 178. 2022–2023 Top 10 HEOR Trends. Accessed July 19, 2023. <https://www.ispor.org/heor-resources/about-heor/top-10-heor-trends>
 179. Marth K, Focke-Tejkl M, Lupinek C, Valenta R, Niederberger V. Allergen peptides, recombinant allergens and Hypoallergens for allergen-specific immunotherapy. *Curr Treat Options Allergy*. 2014;1(1):91-106. doi:10.1007/s40521-013-0006-5
 180. Zhernov Y, Curin M, Khaitov M, Karaulov A, Valenta R. Recombinant allergens for immunotherapy: state of the art. *Curr Opin Allergy Clin Immunol*. 2019;19(4):402-414. doi:10.1097/ACI.0000000000000536
 181. Maasch HJ, Marsh DG. Standardized extracts modified allergens-allergoids. *Clin Rev Allergy*. 1987;5(1):89-106. doi:10.1007/BF02802259
 182. Puttonen E, Maasch HJ, Pilström L. Studies of allergen and allergoid preparations from purified timothy (*Phleum pratense*) pollen extracts. I. Physicochemical characteristics and binding to allergen-specific human IgE. *Int Arch Allergy Appl Immunol*. 1982;68(1):1-6. doi:10.1159/000233058
 183. Klimek L, Bachert C, Lukat KF, Pfaar O, Meyer H, Narkus A. Allergy immunotherapy with a hypoallergenic recombinant birch pollen allergen rBet v 1-FV in a randomized controlled trial. *Clin Transl Allergy*. 2015;5:28. doi:10.1186/s13601-015-0071-x
 184. Grilo JR, Kitzmüller C, Aglas L, et al. IgE-cross-blocking antibodies to Fagales following sublingual immunotherapy with recombinant bet v 1. *Allergy*. 2021;76(8):2555-2564. doi:10.1111/all.14817
 185. Niederberger V, Neubauer A, Gevaert P, et al. Safety and efficacy of immunotherapy with the recombinant B-cell epitope-based grass pollen vaccine BM32. *J Allergy Clin Immunol*. 2018;142(2):497-509. e9. doi:10.1016/j.jaci.2017.09.052
 186. Eckl-Dorna J, Weber M, Stanek V, et al. Two years of treatment with the recombinant grass pollen allergy vaccine BM32 induces a continuously increasing allergen-specific IgG4 response. *EBioMedicine*. 2019;50:421-432. doi:10.1016/j.ebiom.2019.11.006
 187. Rauber MM, Möbs C, Campana R, et al. Allergen immunotherapy with the hypoallergenic B-cell epitope-based vaccine BM32 modifies IL-10- and IL-5-secreting T cells. *Allergy*. 2020;75(2):450-453. doi:10.1111/all.13996
 188. Rudulier CD, Tonti E, James E, Kwok WW, Larché M. Modulation of CRTh2 expression on allergen-specific T cells following peptide immunotherapy. *Allergy*. 2019;74(11):2157-2166. doi:10.1111/all.13867
 189. Pellaton C, Perrin Y, Boudousquie C, et al. Novel birch pollen specific immunotherapy formulation based on contiguous overlapping peptides. *Clin Transl Allergy*. 2013;3(1):17. doi:10.1186/2045-7022-3-17
 190. Orengo JM, Radin AR, Kamat V, et al. Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement. *Nat Commun*. 2018;9(1):1421. doi:10.1038/s41467-018-03636-8
 191. Gevaert P, De Craemer J, De Ruyc N, et al. Novel antibody cocktail targeting bet v 1 rapidly and sustainably treats birch allergy symptoms in a phase 1 study. *J Allergy Clin Immunol*. 2022;149(1):189-199. doi:10.1016/j.jaci.2021.05.039
 192. Benito-Villalvilla C, Pérez-Diego M, Angelina A, et al. Allergoid-mannan conjugates reprogram monocytes into tolerogenic dendritic cells via epigenetic and metabolic rewiring. *J Allergy Clin Immunol*. 2022;149(1):212-222.e9. doi:10.1016/j.jaci.2021.06.012
 193. Gamazo C, D'Amelio C, Gastaminza G, Ferrer M, Irache JM. Adjuvants for allergy immunotherapeutics. *Hum Vaccin Immunother*. 2017;13(10):2416-2427. doi:10.1080/21645515.2017.1348447
 194. Florido-López JF, Andreu-Balaguer C, Escudero C, et al. Effectiveness and safety of a glutaraldehyde-modified, L-tyrosine-adsorbed and monophosphoryl lipid A-adjuvanted allergen immunotherapy in patients with allergic asthma sensitized to olive pollen: a retrospective, controlled real-world study. *World Allergy Organ J*. 2020;13(12):100487. doi:10.1016/j.waojou.2020.100487
 195. Kitzmüller C, Kalsner J, Mutschlechner S, et al. Fusion proteins of flagellin and the major birch pollen allergen bet v 1 show enhanced immunogenicity, reduced allergenicity, and intrinsic adjuvanticity. *J Allergy Clin Immunol*. 2018;141(1):293-299.e6. doi:10.1016/j.jaci.2017.02.044
 196. Montamat G, Leonard C, Poli A, Klimek L, Ollert M. CpG adjuvant in allergen-specific immunotherapy: finding the sweet spot for the induction of immune tolerance. *Front Immunol*. 2021;12:590054. doi:10.3389/fimmu.2021.590054
 197. Anzaghe M, Schülke S, Scheurer S. Virus-like particles as carrier systems to enhance immunomodulation in allergen immunotherapy. *Curr Allergy Asthma Rep*. 2018;18(12):71. doi:10.1007/s11882-018-0827-1
 198. Senti G, Johansen P, Haug S, et al. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial. *Clin Exp Allergy*. 2009;39(4):562-570. doi:10.1111/j.1365-2222.2008.03191.x
 199. Longo A, Longo V, Colombo P. Nanoparticles in allergen immunotherapy. *Curr Opin Allergy Clin Immunol*. 2021;21(6):576-582. doi:10.1097/ACI.0000000000000782
 200. Feng Z, Yi X, Hajavi J. New and old adjuvants in allergen-specific immunotherapy: with a focus on nanoparticles. *J Cell Physiol*. 2021;236(2):863-876. doi:10.1002/jcp.29941
 201. Jutel M, Torres MJ, Palomares O, et al. COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals-EAACI recommendations. *Allergy*. 2022;77(8):2313-2336. doi:10.1111/all.15252
 202. Corren J, Saini SS, Gagnon R, et al. Short-term subcutaneous allergy immunotherapy and dupilumab are well tolerated in allergic

- rhinitis: a randomized trial. *J Asthma Allergy*. 2021;14:1045-1063. doi:10.2147/JAA.S318892
203. Hoshino M, Akitsu K, Kubota K, Ohtawa J. Efficacy of a house dust mite sublingual immunotherapy tablet as add-on dupilumab in asthma with rhinitis. *Allergol Int*. 2022;71(4):490-497. doi:10.1016/j.alit.2022.05.010
204. Sindher SB, Kumar D, Cao S, et al. Phase 2, randomized multi oral immunotherapy with omalizumab 'real life' study. *Allergy*. 2022;77(6):1873-1884. doi:10.1111/all.15217
205. Manohar M, Dunham D, Gupta S, et al. Immune changes beyond Th2 pathways during rapid multifood immunotherapy enabled with omalizumab. *Allergy*. 2021;76(9):2809-2826. doi:10.1111/all.14833
206. Zuberbier T, Wood RA, Bindslev-Jensen C, et al. Omalizumab in IgE-mediated food allergy: A systematic review and meta-analysis. *J Allergy Clin Immunol Pract*. 2023;11(4):1134-1146. doi:10.1016/j.jaip.2022.11.036
207. Massanari M, Nelson H, Casale T, et al. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. *J Allergy Clin Immunol*. 2010;125(2):383-389. doi:10.1016/j.jaci.2009.11.022
208. Valdesoiro-Navarrete L, León ME, Rodríguez M, et al. Combination therapy of specific aeroallergens immunotherapy and omalizumab, in children with severe asthma. *Allergol Immunopathol (Madr)*. 2022;50(2):1-6. doi:10.15586/aei.v50i2.469
209. Stretz E, Ooppel EM, Råwær HC, et al. Overcoming severe adverse reactions to venom immunotherapy using anti-IgE antibodies in combination with a high maintenance dose. *Clin Exp Allergy*. 2017;47(12):1631-1639. doi:10.1111/cea.12997
210. Yee CSK, Albuhairei S, Noh E, et al. Long-term outcome of Peanut Oral immunotherapy facilitated initially by omalizumab. *J Allergy Clin Immunol Pract*. 2019;7(2):451-461.e7. doi:10.1016/j.jaip.2018.09.015
211. Corren J, Larson D, Altman MC, et al. Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: a randomized controlled trial. *J Allergy Clin Immunol*. 2023;151(1):192-201. doi:10.1016/j.jaci.2022.08.029
212. Agache I, Eguiluz-Gracia I, Cojanu C, et al. Advances and highlights in asthma in 2021. *Allergy*. 2021;76(11):3390-3407. doi:10.1111/all.15054
213. Agache I, Zemelka-Wiacek M, Shamji MH, Jutel M. Immunotherapy: state-of-the-art review of therapies and theratypes. *J Allergy Clin Immunol*. 2022;150(6):1279-1288. doi:10.1016/j.jaci.2022.10.007
214. Palomares O, Akdis M, Martín-Fontecha M, Akdis CA. Mechanisms of immune regulation in allergic diseases: the role of regulatory T and B cells. *Immunol Rev*. 2017;278(1):219-236. doi:10.1111/imr.12555
215. Virchow JC, Backer V, Kuna P, et al. Efficacy of a house dust mite sublingual allergen immunotherapy tablet in adults with allergic asthma: a randomized clinical trial. *JAMA*. 2016;315(16):1715-1725. doi:10.1001/jama.2016.3964
216. Mosbech H, Deckelmann R, de Blay F, et al. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial. *J Allergy Clin Immunol*. 2014;134(3):568-575.e7. doi:10.1016/j.jaci.2014.03.019
217. Agache I, Antolin-Amerigo D, de Blay F, et al. EAACI position paper on the clinical use of the bronchial allergen challenge: unmet needs and research priorities. *Allergy*. 2022;77(6):1667-1684. doi:10.1111/all.15203
218. Agache I, Lau S, Akdis CA, et al. EAACI guidelines on allergen immunotherapy: house dust mite-driven allergic asthma. *Allergy*. 2019;74(5):855-873. doi:10.1111/all.13749
219. Shamji MH, Valenta R, Jardetzky T, et al. The role of allergen-specific IgE, IgG and IgA in allergic disease. *Allergy*. 2021;76(12):3627-3641. doi:10.1111/all.14908
220. Shamji MH, Layhadi JA, Achkova D, et al. Role of IL-35 in sublingual allergen immunotherapy. *J Allergy Clin Immunol*. 2019;143(3):1131-1142.e4. doi:10.1016/j.jaci.2018.06.041
221. Wahn U, Bachert C, Heinrich J, Richter H, Zielen S. Real-world benefits of allergen immunotherapy for birch pollen-associated allergic rhinitis and asthma. *Allergy*. 2019;74(3):594-604. doi:10.1111/all.13598
222. Sánchez J, Alvarez L, García E. Real-world study: drug reduction in children with allergic rhinitis and asthma receiving immunotherapy. *Immunotherapy*. 2023;15(4):253-266. doi:10.2217/imt-2022-0215
223. Jutel M, Rudert M, Kreimendahl F, Kuna P. Efficacy and tolerability of a house dust mite allergoid in allergic bronchial asthma: a randomized dose-ranging trial. *Immunotherapy*. 2018;10(13):1149-1161. doi:10.2217/imt-2018-0087
224. Woehlk C, Ramu S, Sverrild A, et al. Allergen immunotherapy enhances airway epithelial antiviral immunity in patients with allergic asthma (VITAL study): a double-blind randomized controlled trial. *Am J Respir Crit Care Med*. 2023;207(9):1161-1170. doi:10.1164/rccm.202209-1708OC
225. Woehlk C, Von Bülow A, Ghanizada M, Søndergaard MB, Hansen S, Porsbjerg C. Allergen immunotherapy effectively reduces the risk of exacerbations and lower respiratory tract infections in both seasonal and perennial allergic asthma: a nationwide epidemiological study. *Eur Respir J*. 2022;60(5):2200446. doi:10.1183/13993003.00446-2022
226. Incorvaia C, Al-Ahmad M, Ansotegui IJ, et al. Personalized medicine for allergy treatment: allergen immunotherapy still a unique and unmatched model. *Allergy*. 2021;76(4):1041-1052. doi:10.1111/all.14575
227. Global strategy for asthma management and prevention. Accessed July 19, 2023. <https://ginasthma.org/wp-content/uploads/2019/01/2017-GINA.pdf>

How to cite this article: Zemelka-Wiacek M, Agache I, Akdis CA, et al. Hot topics in allergen immunotherapy, 2023: Current status and future perspective. *Allergy*. 2023;00:1-20. doi:10.1111/all.15945